pHLIP® peptide-mediated epitope tethering at cell surfaces

ABSTRACT

The invention features methods and compositions for eliciting an anti-tumor response in a subject comprising administering to the subject a pHLIP® construct comprising an antibody recruiting molecule linked to one or more pHLIP® peptides by a non-cleavable linker compound. The construct increases the amount of the antibody recruiting molecule on the surface of a diseased cell.

RELATED APPLICATIONS

This application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62/797,899, filed Jan. 28, 2019, the entire contents of which is incorporated herein by reference in its entirety.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with government support under R01 GM073857 awarded by the National Institute of General Medical Sciences of the National Institutes of Health. The government has certain rights in the invention.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING

The contents of the sequence listing text file named “040984-512001WO_SL.txt”, which was created on Jan. 28, 2020 and is 222 kilobytes in size, is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to immunotherapy.

BACKGROUND

Antibody therapies are based on the alteration of signaling, promotion of apoptosis, sequestration of growth factors, activation of the immune system, and delivery of drugs as antibody-drug conjugates (ADCs). Antibodies find their target cells by recognizing specific signaling molecules (epitopes) exposed by a cell. Epitopes bind and/or attract endogenous (natural) antibodies, exogenous antibodies, ADCs administrated into the body, or antibodies which are produced (generated) in the course of vaccination. Also cytokines, which are small immune-modulating proteins can activate or suppress an immune response depending on their features, concentration and local environment. Numerous highly specific humanized monoclonal antibodies such as trastuzumab (Herceptin), and antibody-cytokine fusion proteins have been developed and are in clinical use (or clinical trials), which target epitopes that are more abundant in a diseased tissue than in a normal tissue. However, their use is limited by (1) the lack of adequate amounts (or any amounts) of accessible epitopes in many cancers, and (2) the emergence of resistance by selection of expression mutants not presenting proper epitopes.

SUMMARY OF THE INVENTION

The invention provides a solution to the limitations of existing therapeutic approaches by utilizing a strategy in which a desired epitope is positioned on cell surfaces in diseased tissues, such as tumors or inflamed tissues. Positioning the epitope on the cell surface, (e.g., preferentially in diseased tissues), is a great advantage and enhances the recruitment of cells of the immune system or endogenous antibodies, and enhances the use of developed monoclonal antibodies such as trastuzumab (Herceptin), antibody-drug conjugates, and antibodies generated in the course of vaccination. The invention further provides compositions and methods to augment any amount of particular epitopes at cell surfaces for immunoregulation and efficient binding of immune cells, antibodies and ADCs.

Provided herein are compositions and methods for the decoration of target cells with epitopes, e.g., a protein, a peptide, or a small molecule epitope, that can (1) recruit immune cells (or exogenous engineered T-cells and NK-cells), (2) recruit endogenous antibodies, (3) enhance the use of the exogenous antibodies or ADCs administrated into body, and (4) enhance the use of antibodies, which are produced (generated) in the course of vaccination leading to cell death.

Tumors are characterized by a tumor micro environment (TME) of a lower pH than the surrounding tissues, because of the metabolism accompanying their rapid and uncontrolled cell proliferation, which results in a flux of acidity emerging from the cancer cells. Moreover, due to the flux and the membrane potential, the extracellular pH is lowest at the surfaces of cancer cells and is significantly lower than the bulk extracellular pH in tumors. The low pH region persists at the cancer cell surfaces even in well-perfused tumor areas.

A pH Low Insertion Peptide (pHLIP®) is a water-soluble membrane peptide that interacts weakly with a cell membrane at neutral pH, without insertion into the lipid bilayer; however, at slightly acidic pH (<7.0), a pHLIP® inserts into the cell membrane and, if it is long enough and non-cyclic, can form a stable transmembrane alpha-helix. In addition to tumor cells characterized by low pH (<7.0), immune cells within a tumor mass are also characterized by low pH (<7.0). For example, the cells within the environment of a tumor mass, e.g., macrophages, are also characterized by a low surface pH.

By binding (linking and/or conjugating) a pHLIP®, or pHLIP® equivalent, to an epitope, it is possible to specifically target the cell and decorate a tumor cell or cells in inflamed tissues with epitopes to recognize or recruit endogenous (natural) immune cells or antibodies circulating in the blood, promote and enhance binding of exogenous engineered T-cells and NK-cells or antibodies or ADCs administrated into body, or antibodies, which are generated in the course of vaccination and thereby promote cell killing. A significant advantage of this approach is that the pHLIP® constructs described herein are associated with few to no side effects for the patient due to the targeted delivery of epitopes to the cell surfaces. The epitope may be of mammalian origin, viral origin, or bacterial origin.

Accordingly, the invention features a composition comprising an epitope conjugated to a pH-triggered membrane peptide (pHLIP®) comprising at least 4 amino acids. For example, the pHLIP® peptide may be a linear peptide or a cyclic peptide, e.g., as described in PCT Application No. PCT/US2017/023458. The epitope is selectively positioned on the surface of the cell in targeted diseased tissue by pHLIP® to mediate or enhance immune cells (lymphocytes) recruitment and adhesion, antibody binding and induce cell killing predominantly in diseased tissue (tumor). The composition comprises an epitope conjugated to pHLIP®, and the pHLIP® targets epitope to the cell surface.

Accordingly, the method of eliciting an anti-tumor response in a subject comprises administering to a subject, e.g., a human subject, a pHLIP® construct comprising an antibody or lymphocyte recruiting molecule linked to one or more pHLIP® peptides by a non-cleavable linker compound, wherein the construct increases the amount of the immune cell or the antibody recruiting molecule on the surface of a diseased cell. For example, the diseased cell comprises a tumor cell.

In some examples, the antibody recruiting molecule comprises an epitope, e.g., an epitope (e.g., a peptide epitope) with a length less than 500 amino acids. For example, the peptide epitope comprises a length of between 5 to 20 amino acids, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids. In some embodiments, the peptide epitope is a human epidermal growth factor 2 (HER2) peptide, e.g., a HER2 peptide selected from the group consisting of QVSHWVSGLAEGSFG (SEQ ID NO: 1), LSHTSGRVEGSVSLL (SEQ ID NO: 2), and QMWAPQWGPD (SEQ ID NO: 3).

The human amino acid sequence of HER2 is provided below and is incorporated herein by reference (NCBI GenBank NP_001005862.1 or UniProt P04626).

(SEQ ID NO:   ) 1 mklrlpaspe thldmlrhly qgcqvvqgnl eltylptnas lsflqdiqev qgyvliahnq 61 vrqvplqrlr ivrgtqlfed nyalavldng dplnnttpvt gaspgglrel qlrslteilk 121 ggvliqrnpq lcyqdtilwk difhknnqla ltlidtnrsr achpcspmck gsrcwgesse 181 dcqsltrtvc aggcarckgp lptdccheqc aagctgpkhs dclaclhfnh sgicelhcpa 241 lvtyntdtfe smpnpegryt fgascvtacp ynylstdvgs ctlvcplhnq evtaedgtqr 301 cekcskpcar vcyglgmehl revravtsan iqefagckki fgslaflpes fdgdpasnta 361 plqpeqlqvf etleeitgyl yisawpdslp dlsvfqnlqv irgrilhnga ysltlqglgi 421 swlglrslre lgsglalihh nthlcfvhtv pwdqlfrnph qallhtanrp edecvgegla 481 chqlcarghc wgpgptqcvn csqflrgqec veecrvlqgl preyvnarhc lpchpecqpq 541 ngsvtcfgpe adqcvacahy kdppfcvarc psgvkpdlsy mpiwkfpdee gacqpcpinc 601 thscvdlddk gcpaeqrasp ltsiisavvg illvvvlgvv fgilikrrqq kirkytmrrl 661 lqetelvepl tpsgampnqa qmrilketel rkvkvlgsga fgtvykgiwi pdgenvkipv 721 aikvlrents pkankeilde ayvmagvgsp yvsrllgicl tstvqlvtql mpygclldhv 781 renrgrlgsq dllnwcmqia kgmsyledvr lvhrdlaarn vlvkspnhvk itdfglarll 841 dideteyhad ggkvpikwma lesilrrrft hqsdvwsygv tvwelmtfga kpydgipare 901 ipdllekger lpqppictid vymimvkcwm idsecrprfr elvsefsrma rdpqrfvviq 961 nedlgpaspl dstfyrslle dddmgdlvda eeylvpqqgf fcpdpapgag gmvhhrhrss 1021 strsgggdlt lglepseeea prsplapseg agsdvfdgdl gmgaakglqs lpthdpsplq 1081 rysedptvpl psetdgyvap ltcspqpeyv nqpdvrpqpp spregplpaa rpagatlerp 1141 ktlspgkngv vkdvfafgga venpeyltpq ggaapqphpp pafspafdnl yywdqdpper 1201 gappstfkgt ptaenpeylg ldvpv

Exemplary landmark residues, domains, and fragments of HER2 include, but are not limited to residues 22-143 (Receptor L domain), residues 159-308 (furin like domain), or 611-654 (transmembrane domain of Erb2 (receptor tyrosine-protein kinase). A fragment (e.g., a peptide or an epitope) of a HER2 protein is less than the length of the full length protein, e.g., a fragment is at least 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 200 or more residues in length, but less than e.g., 1225 residues in the case of HER2 above. Additionally, HER2 may include a signal sequence (melaalcrwglllallppgaastqvctgtd SEQ ID NO: 516, which gets cleaved to form the mature protein).

The human HER2 nucleic acid sequence is provided below and is incorporated herein by reference (start and stop codons are underlined; NCBI GenBank: NM_001005862.2).

1 aagttcctgt gttctttatt ctactctccg ctgaagtcca cacagtttaa attaaagttc 61 ccggattttt gtgggcgcct gccccgcccc tcgtccccct gctgtgtcca tatatcgagg 121 cgatagggtt aagggaaggc ggacgcctga tgggttaatg agcaaactga agtgttttcc 181 atgatctttt ttgagtcgca attgaagtac cacctcccga gggtgattgc ttccccatgc 241 ggggtagaac ctttgctgtc ctgttcacca ctctacctcc agcacagaat ttggcttatg 301 cctactcaat gtgaagatga tgaggatgaa aacctttgtg atgatccact tccacttaat 361 gaatggtggc aaagcaaagc tatattcaag accacatgca aagctactcc ctgagcaaag 421 agtcacagat aaaacggggg caccagtaga atggccagga caaacgcagt gcagcacaga 481 gactcagacc ctggcagcca tgcctgcgca ggcagtgatg agagtgacat gtactgttgt 541 ggacatgcac aaaagtgagt gtgcaccggc acagac atg a agctgcggct ccctgccagt 601 cccgagaccc acctggacat gctccgccac ctctaccagg gctgccaggt ggtgcaggga 661 aacctggaac tcacctacct gcccaccaat gccagcctgt ccttcctgca ggatatccag 721 gaggtgcagg gctacgtgct catcgctcac aaccaagtga ggcaggtccc actgcagagg 781 ctgcggattg tgcgaggcac ccagctcttt gaggacaact atgccctggc cgtgctagac 841 aatggagacc cgctgaacaa taccacccct gtcacagggg cctccccagg aggcctgcgg 901 gagctgcagc ttcgaagcct cacagagatc ttgaaaggag gggtcttgat ccagcggaac 961 ccccagctct gctaccagga cacgattttg tggaaggaca tcttccacaa gaacaaccag 1021 ctggctctca cactgataga caccaaccgc tctcgggcct gccacccctg ttctccgatg 1081 tgtaagggct cccgctgctg gggagagagt tctgaggatt gtcagagcct gacgcgcact 1141 gtctgtgccg gtggctgtgc ccgctgcaag gggccactgc ccactgactg ctgccatgag 1201 cagtgtgctg ccggctgcac gggccccaag cactctgact gcctggcctg cctccacttc 1261 aaccacagtg gcatctgtga gctgcactgc ccagccctgg tcacctacaa cacagacacg 1321 tttgagtcca tgcccaatcc cgagggccgg tatacattcg gcgccagctg tgtgactgcc 1381 tgtccctaca actacctttc tacggacgtg ggatcctgca ccctcgtctg ccccctgcac 1441 aaccaagagg tgacagcaga ggatggaaca cagcggtgtg agaagtgcag caagccctgt 1501 gcccgagtgt gctatggtct gggcatggag cacttgcgag aggtgagggc agttaccagt 1561 gccaatatcc aggagtttgc tggctgcaag aagatctttg ggagcctggc atttctgccg 1621 gagagctttg atggggaccc agcctccaac actgccccgc tccagccaga gcagctccaa 1681 gtgtttgaga ctctggaaga gatcacaggt tacctataca tctcagcatg gccggacagc 1741 ctgcctgacc tcagcgtctt ccagaacctg caagtaatcc ggggacgaat tctgcacaat 1801 ggcgcctact cgctgaccct gcaagggctg ggcatcagct ggctggggct gcgctcactg 1861 agggaactgg gcagtggact ggccctcatc caccataaca cccacctctg cttcgtgcac 1921 acggtgccct gggaccagct ctttcggaac ccgcaccaag ctctgctcca cactgccaac 1981 cggccagagg acgagtgtgt gggcgagggc ctggcctgcc accagctgtg cgcccgaggg 2041 cactgctggg gtccagggcc cacccagtgt gtcaactgca gccagttcct tcggggccag 2101 gagtgcgtgg aggaatgccg agtactgcag gggctcccca gggagtatgt gaatgccagg 2161 cactgtttgc cgtgccaccc tgagtgtcag ccccagaatg gctcagtgac ctgttttgga 2221 ccggaggctg accagtgtgt ggcctgtgcc cactataagg accctccctt ctgcgtggcc 2281 cgctgcccca gcggtgtgaa acctgacctc tcctacatgc ccatctggaa gtttccagat 2341 gaggagggcg catgccagcc ttgccccatc aactgcaccc actcctgtgt ggacctggat 2401 gacaagggct gccccgccga gcagagagcc agccctctga cgtccatcat ctctgcggtg 2461 gttggcattc tgctggtcgt ggtcttgggg gtggtctttg ggatcctcat caagcgacgg 2521 cagcagaaga tccggaagta cacgatgcgg agactgctgc aggaaacgga gctggtggag 2581 ccgctgacac ctagcggagc gatgcccaac caggcgcaga tgcggatcct gaaagagacg 2641 gagctgagga aggtgaaggt gcttggatct ggcgcttttg gcacagtcta caagggcatc 2701 tggatccctg atggggagaa tgtgaaaatt ccagtggcca tcaaagtgtt gagggaaaac 2761 acatccccca aagccaacaa agaaatctta gacgaagcat acgtgatggc tggtgtgggc 2821 tccccatatg tctcccgcct tctgggcatc tgcctgacat ccacggtgca gctggtgaca 2881 cagcttatgc cctatggctg cctcttagac catgtccggg aaaaccgcgg acgcctgggc 2941 tcccaggacc tgctgaactg gtgtatgcag attgccaagg ggatgagcta cctggaggat 3001 gtgcggctcg tacacaggga cttggccgct cggaacgtgc tggtcaagag tcccaaccat 3061 gtcaaaatta cagacttcgg gctggctcgg ctgctggaca ttgacgagac agagtaccat 3121 gcagatgggg gcaaggtgcc catcaagtgg atggcgctgg agtccattct ccgccggcgg 3181 ttcacccacc agagtgatgt gtggagttat ggtgtgactg tgtgggagct gatgactttt 3241 ggggccaaac cttacgatgg gatcccagcc cgggagatcc ctgacctgct ggaaaagggg 3301 gagcggctgc cccagccccc catctgcacc attgatgtct acatgatcat ggtcaaatgt 3361 tggatgattg actctgaatg tcggccaaga ttccgggagt tggtgtctga attctcccgc 3421 atggccaggg acccccagcg ctttgtggtc atccagaatg aggacttggg cccagccagt 3481 cccttggaca gcaccttcta ccgctcactg ctggaggacg atgacatggg ggacctggtg 3541 gatgctgagg agtatctggt accccagcag ggcttcttct gtccagaccc tgccccgggc 3601 gctgggggca tggtccacca caggcaccgc agctcatcta ccaggagtgg cggtggggac 3661 ctgacactag ggctggagcc ctctgaagag gaggccccca ggtctccact ggcaccctcc 3721 gaaggggctg gctccgatgt atttgatggt gacctgggaa tgggggcagc caaggggctg 3781 caaagcctcc ccacacatga ccccagccct ctacagcggt acagtgagga ccccacagta 3841 cccctgccct ctgagactga tggctacgtt gcccccctga cctgcagccc ccagcctgaa 3901 tatgtgaacc agccagatgt tcggccccag cccccttcgc cccgagaggg ccctctgcct 3961 gctgcccgac ctgctggtgc cactctggaa aggcccaaga ctctctcccc agggaagaat 4021 ggggtcgtca aagacgtttt tgcctttggg ggtgccgtgg agaaccccga gtacttgaca 4081 ccccagggag gagctgcccc tcagccccac cctcctcctg ccttcagccc agccttcgac 4141 aacctctatt actgggacca ggacccacca gagcgggggg ctccacccag caccttcaaa 4201 gggacaccta cggcagagaa cccagagtac ctgggtctgg acgtgccagt g tga accaga 4261 aggccaagtc cgcagaagcc ctgatgtgtc ctcagggagc agggaaggcc tgacttctgc 4321 tggcatcaag aggtgggagg gccctccgac cacttccagg ggaacctgcc atgccaggaa 4381 cctgtcctaa ggaaccttcc ttcctgcttg agttcccaga tggctggaag gggtccagcc 4441 tcgttggaag aggaacagca ctggggagtc tttgtggatt ctgaggccct gcccaatgag 4501 actctagggt ccagtggatg ccacagccca gcttggccct ttccttccag atcctgggta 4561 ctgaaagcct tagggaagct ggcctgagag gggaagcggc cctaagggag tgtctaagaa 4621 caaaagcgac ccattcagag actgtccctg aaacctagta ctgcccccca tgaggaagga 4681 acagcaatgg tgtcagtatc caggctttgt acagagtgct tttctgttta gtttttactt 4741 tttttgtttt gtttttttaa agatgaaata aagacccagg gggagaatgg gtgttgtatg 4801 gggaggcaag tgtggggggt ccttctccac acccactttg tccatttgca aatatatttt 4861 ggaaaacagc taaaaaaaaa aaaaaaaaa

(SEQ ID NO: 514)

Exemplary landmark residues, domains, and fragments of HER2 include, but are not limited to residues 57-4254 (coding region), residues 4767-4772 (polyA signal sequence), 4787 (polyA site), or 4872 (polyA site).

In other example, the peptide (epitope peptide) comprises a mammalian peptide, a viral peptide, or a bacterial peptide. For example, the peptide is selected from the group consisting of MASMTGGQQMG (SEQ ID NO: 4)—T7 peptide derived from the T7 major capsid protein; EQKLISEEDL (SEQ ID NO: 5)—Myc peptide derived from c-Myc; YPYDVPDYA (SEQ ID NO: 6)—hemagglutinin (HA) peptide derived from hemagglutinin; YTDIEMNRLGK (SEQ ID NO: 7)—vesiculovirus (VSV-G) peptide derived from the vesicular stomatitis viral glycoprotein; KETAAAKFERQHMDS (SEQ ID NO: 8)—S peptide derived from pancreatic ribonuclease A; GKPIPNPLLGLDST (SEQ ID NO: 9)—V5 peptide derived from the P and V proteins of the paramyxovirus of simian virus 5; DYKDDDDK (SEQ ID NO: 10)—FLAG synthetic peptide; GAPVPYPDPLEPR (SEQ ID NO: 11)—E synthetic peptide; HHHHHH (SEQ ID NO: 12)—Histidine synthetic peptide; TKENPRSNQEESYDDNES (SEQ ID NO: 13)—NE-tag synthetic peptide; WSHPQFEK (SEQ ID NO: 14)—synthetic peptide recognized by streptavidin; PDRVRAVSHWSS (SEQ ID NO: 15)—peptide derived from the protein beta-catenin and optimized for higher affinity binding to the Spot-Tag Nanobody; and YTDIEMNRLGK (SEQ ID NO: 7)—vesicular stomatitis virus (VSV) synthetic peptide.

In some examples, the immune cell (e.g., a lymphocyte) recruiting molecule comprises a cytokine protein or a cytokine protein epitope. For example, the cytokine protein is less than 200 amino acids. In other examples, the cytokine protein is up to 350 amino acids. Exemplary cytokine protein epitopes include interleukin 2 (IL-2), interleukin 6 (IL-6), interleukin-7 (IL-7), interleukin-12 (IL-12), a tumor necrosis factor (TNF), or chemokines including α-chemokines or CXC chemokines, where CXC stands for Cys-X-Cys motif, and β-chemokines or CC chemokines, where CC stands for Cys-Cys motif near their amino terminus.

An exemplary chemokine comprises the human protein epitope C-X-C motif chemokine 10 (CXCL10) or Interferon gamma-induced protein 10 (IP-10) (UniProt P02778 or NP_001556.2, incorporated herein by reference), and an exemplary sequence comprises the amino acid sequence:

1 mnqtailicc lifltlsgiq gvplsrtvrc tcisisnqpv nprsleklei 61 ipasqfcprv eiiatmkkkg ekrclnpesk aiknllkavs kerskrsp

(SEQ ID NO: 514)

Exemplary landmark residues, domains, and fragments of CXCL10 include, but are not limited to residues 1-21 (signal peptide), residues 22-98 (mature peptide). A fragment (e.g., a peptide or an epitope) of a CXCL10 protein is less than the length of the full length protein, e.g., a fragment is at least 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100 or more residues in length, but less than e.g., 108 residues in the case of CXCL10 above.

The human CXCL10 nucleic acid sequence is provided below and is incorporated herein by reference (start and stop codons are underlined; NCBI GenBank: NM_001565.4).

1 gagacattcc tcaattgctt agacatattc tgagcctaca gcagaggaac ctccagtctc 61 agcacc atg a atcaaactgc cattctgatt tgctgcctta tctttctgac tctaagtggc 121 attcaaggag tacctctctc tagaactgta cgctgtacct gcatcagcat tagtaatcaa 181 cctgttaatc caaggtcttt agaaaaactt gaaattattc ctgcaagcca attttgtcca 241 cgtgttgaga tcattgctac aatgaaaaag aagggtgaga agagatgtct gaatccagaa 301 tcgaaggcca tcaagaattt actgaaagca gttagcaagg aaaggtctaa aagatctcct 361 taa aaccaga ggggagcaaa atcgatgcag tgcttccaag gatggaccac acagaggctg 421 cctctcccat cacttcccta catggagtat atgtcaagcc ataattgttc ttagtttgca 481 gttacactaa aaggtgacca atgatggtca ccaaatcagc tgctactact cctgtaggaa 541 ggttaatgtt catcatccta agctattcag taataactct accctggcac tataatgtaa 601 gctctactga ggtgctatgt tcttagtgga tgttctgacc ctgcttcaaa tatttccctc 661 acctttccca tcttccaagg gtactaagga atctttctgc tttggggttt atcagaattc 721 tcagaatctc aaataactaa aaggtatgca atcaaatctg ctttttaaag aatgctcttt 781 acttcatgga cttccactgc catcctccca aggggcccaa attctttcag tggctaccta 841 catacaattc caaacacata caggaaggta gaaatatctg aaaatgtatg tgtaagtatt 901 cttatttaat gaaagactgt acaaagtaga agtcttagat gtatatattt cctatattgt 961 tttcagtgta catggaataa catgtaatta agtactatgt atcaatgagt aacaggaaaa 1021 ttttaaaaat acagatagat atatgctctg catgttacat aagataaatg tgctgaatgg 1081 ttttcaaaat aaaaatgagg tactctcctg gaaatattaa gaaagactat ctaaatgttg 1141 aaagatcaaa aggttaataa agtaattata actaa

(SEQ ID NO: 517)

Exemplary landmark residues, domains, and fragments of CXCL10 include, but are not limited to residues 67-129 (signal peptide), residues 130-360 (mature peptide), or residues 67-363 (coding region).

The human amino acid sequence of CXCL9 is provided below and is incorporated herein by reference (NCBI GenBank NP_002407.1 or UniProt Q07325):

(SEQ ID NO: 518) 1 mkksqvlfll giillvligv qgtpvvrkgr cscistnqgt ihlqslkdlk qfapspscek 61 ieiiatlkng vqtclnpdsa dvkelikkwe kqvsqkkkqk ngkkhqkkkv lkvrksqrsr 121 qkktt

Exemplary landmark residues, domains, and fragments of CXCL9 include, but are not limited to residues 1-22 (signal peptide) or residues 23-125 (mature peptide). A fragment (e.g., a peptide or an epitope) of a CXCL9 protein is less than the length of the full length protein, e.g., a fragment is at least 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100 or more residues in length, but less than e.g., 125 residues in the case of CXCL9 above.

The human CXCL9 nucleic acid sequence is provided below and is incorporated herein by reference (start and stop codons are underlined; NCBI GenBank: NM_002416.3).

SEQ ID NO: 519 1 aaagaatttc tcaggctcaa aatccaatac aggagtgact tggaactcca ttctatcact 61 atg aagaaaa gtggtgttct tttcctcttg ggcatcatct tgctggttct gattggagtg 121 caaggaaccc cagtagtgag aaagggtcgc tgttcctgca tcagcaccaa ccaagggact 181 atccacctac aatccttgaa agaccttaaa caatttgccc caagcccttc ctgcgagaaa 241 attgaaatca ttgctacact gaagaatgga gttcaaacat gtctaaaccc agattcagca 301 gatgtgaagg aactgattaa aaagtgggag aaacaggtca gccaaaagaa aaagcaaaag 361 aatgggaaaa aacatcaaaa aaagaaagtt ctgaaagttc gaaaatctca acgttctcgt 421 caaaagaaga ctaca taa ga gaccacttca ccaataagta ttctgtgtta aaaatgttct 481 attttaatta taccgctatc attccaaagg aggatggcat ataatacaaa ggcttattaa 541 tttgactaga aaatttaaaa cattactctg aaattgtaac taaagttaga aagttgattt 601 taagaatcca aacgttaaga attgttaaag gctatgattg tctttgttct tctaccaccc 661 accagttgaa tttcatcatg cttaaggcca tgattttagc aatacccatg tctacacaga 721 tgttcaccca accacatccc actcacaaca gctgcctgga agagcagccc taggcttcca 781 cgtactgcag cctccagaga gtatctgagg cacatgtcag caagtcctaa gcctgttagc 841 atgctggtga gccaagcagt ttgaaattga gctggacctc accaagctgc tgtggccatc 901 aacctctgta tttgaatcag cctacaggcc tcacacacaa tgtgtctgag agattcatgc 961 tgattgttat tgggtatcac cactggagat caccagtgtg tggctttcag agcctccttt 1021 ctggctttgg aagccatgtg attccatctt gcccgctcag gctgaccact ttatttcttt 1081 ttgttcccct ttgcttcatt caagtcagct cttctccatc ctaccacaat gcagtgcctt 1141 tcttctctcc agtgcacctg tcatatgctc tgatttatct gagtcaactc ctttctcatc 1201 ttgtccccaa caccccacag aagtgctttc ttctcccaat tcatcctcac tcagtccagc 1261 ttagttcaag tcctgcctct taaataaacc tttttggaca cacaaattat cttaaaactc 1321 ctgtttcact tggttcagta ccacatgggt gaacactcaa tggttaacta attcttgggt 1381 gtttatccta tctctccaac cagattgtca gctccttgag ggcaagagcc acagtatatt 1441 tccctgtttc ttccacagtg cctaataata ctgtggaact aggttttaat aattttttaa 1501 ttgatgttgt tatgggcagg atggcaacca gaccattgtc tcagagcagg tgctggctct 1561 ttcctggcta ctccatgttg gctagcctct ggtaacctct tacttattat cttcaggaca 1621 ctcactacag ggaccaggga tgatgcaaca tccttgtctt tttatgacag gatgtttgct 1681 cagcttctcc aacaataaga agcacgtggt aaaacacttg cggatattct ggactgtttt 1741 taaaaaatat acagtttacc gaaaatcata taatcttaca atgaaaagga ctttatagat 1801 cagccagtga ccaacctttt cccaaccata caaaaattcc ttttcccgaa ggaaaagggc 1861 tttctcaata agcctcagct ttctaagatc taacaagata gccaccgaga tccttatcga 1921 aactcatttt aggcaaatat gagttttatt gtccgtttac ttgtttcaga gtttgtattg 1981 tgattatcaa ttaccacacc atctcccatg aagaaaggga acggtgaagt actaagcgct 2041 agaggaagca gccaagtcgg ttagtggaag catgattggt gcccagttag cctctgcagg 2101 atgtggaaac ctccttccag gggaggttca gtgaattgtg taggagaggt tgtctgtggc 2161 cagaatttaa acctatactc actttcccaa attgaatcac tgctcacact gctgatgatt 2221 tagagtgctg tccggtggag atcccacccg aacgtcttat ctaatcatga aactccctag 2281 ttccttcatg taacttccct gaaaaatcta agtgtttcat aaatttgaga gtctgtgacc 2341 cacttacctt gcatctcaca ggtagacagt atataactaa caaccaaaga ctacatattg 2401 tcactgacac acacgttata atcatttatc atatatatac atacatgcat acactctcaa 2461 agcaaataat ttttcacttc aaaacagtat tgacttgtat accttgtaat ttgaaatatt 2521 ttctttgtta aaatagaatg gtatcaataa atagaccatt aatcagaaaa cagatcttga 2581 ttttttttct cttgaatgta cccttcaact gttgaatgtt taatagtaaa tcttatatgt 2641 ccttatttac tttttagctt tctctcaaat aaagtgtaac actagttgag ataacacatg 2701 aaagctcttt aaagggtcga tcgggaacag gaaaaaaaac ctatggaaaa tatgacaaca 2761 c

Exemplary landmark residues, domains, and fragments of CXCL9 include, but are not limited to residues 61-126 (signal peptide) or residues 127-435 (mature peptide).

The human amino acid sequence of CXCL11 is provided below and is incorporated herein by reference (NCBI GenBank NP_005400.1 or UniProt O14625):

(SEQ ID NO: 520)  1 msvkgmaial avilcatvvq gfpmfkrgrc lcigpgvkav kvadiekasi mypsnncdki 61 eviitlkenk gqrclnpksk qarliikkve rknf

Exemplary landmark residues, domains, and fragments of CXCL11 include, but are not limited to residues 1-21 (signal peptide), residues 22-94 (mature peptide), or residues 28-90 (chemokine-CXC domain). A fragment (e.g., a peptide or an epitope) of a CXCL11 protein is less than the length of the full length protein, e.g., a fragment is at least 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 75 or more residues in length, but less than e.g., 94 residues in the case of CXCL11 above.

The human CXCL11 nucleic acid sequence is provided below and is incorporated herein by reference (start and stop codons are underlined; NCBI GenBank: NM_005409.5).

SEQ ID NO: 521 1 gttcagcatt tctactcctt ccaagaagag cagcaaagct gaagtagcag cagcagcacc 61 agcagcaaca gcaaaaaaca aac atg agtg tgaagggcat ggctatagcc ttggctgtga 121 tattgtgtgc tacagttgtt caaggcttcc ccatgttcaa aagaggacgc tgtctttgca 181 taggccctgg ggtaaaagca gtgaaagtgg cagatattga gaaagcctcc ataatgtacc 241 caagtaacaa ctgtgacaaa atagaagtga ttattaccct gaaagaaaat aaaggacaac 301 gatgcctaaa tcccaaatcg aagcaagcaa ggcttataat caaaaaagtt gaaagaaaga 361 atttt taa aa atatcaaaac atatgaagtc ctggaaaaga gcatctgaaa aacctagaac 421 aagtttaact gtgactactg aaatgacaag aattctacag taggaaactg agacttttct 481 atggttttgt gactttcaac ttttgtacag ttatgtgaag gatgaaaggt gggtgaaagg 541 accaaaaaca gaaatacagt cttcctgaat gaatgacaat cagaattcca ctgcccaaag 601 gagtccaaca attaaatgga tttctaggaa aagctacctt aagaaaggct ggttaccatc 661 ggagtttaca aagtgctttc acgttcttac ttgttgcatt atacattcat gcatttctag 721 gctagagaac cttctagatt tgatgcttac aactattctg ttgtgactat gagaacattt 781 ctgtctctag aagtcatctg tctgtattga tctttatgct atattactat ctgtggttac 841 ggtggagaca ttgacattat tactggagtc aagcccttat aagtcaaaag catctatgtg 901 tcgtaaaaca ttcctcaaac attttttcat gcaaatacac acttctttcc ccaaacatca 961 tgtagcacat caatatgtag ggagacattc ttatgcatca tttggtttgt tttataacca 1021 attcattaaa tgtaattcat aaaatgtact atgaaaaaaa ttatacgcta tgggatactg 1081 gcaaaagtgc acatatttca taaccaaatt agtagcacca gtcttaattt gatgtttttc 1141 aacttttatt cattgagatg ttttgaagca attaggatat gtgtgtttac tgtacttttt 1201 gttttgatcc gtttgtataa atgatagcaa tatcttggac acatctgaaa tacaaaatgt 1261 ttttgtctac caaagaaaaa tgttgaaaaa taagcaaatg tatacctagc aatcactttt 1321 actttttgta attctgtctc ttagaaaaat acataatcta atcaatttct ttgttcatgc 1381 ctatatactg taaaatttag gtatactcaa gactagttta aagaatcaaa gtcatttttt 1441 tctctaataa actaccacaa cctttctttt ttaaaaaaa

Exemplary landmark residues, domains, and fragments of CXCL11 include, but are not limited to residues 84-146 (signal peptide), or residues 147-365 (mature peptide).

The human amino acid sequence of tumor necrosis factor (TNF) is provided below and is incorporated herein by reference (NCBI GenBank NP_000585.2 or (UniProt P01375):

(SEQ ID NO: 522)   1 mstesmirdv elaeealpkk tggpqgsrrc lflslfsfli vagattlfcl lhfgvigpqr  61 eefprdlsli splaqavrss srtpsdkpva hvvanpqaeg qlqwlnrran allangvelr 121 dnqlvvpseg lyliysqvlf kgqgcpsthv lithtisria vsyqtkvnll saikspcqre 181 tpegaeakpw yepiylggvf qlekgdrlsa einrpdyldf aesgqvyfgi ial

Exemplary landmark residues, domains, and fragments of TNF include, but are not limited to residues 1-35 (cytoplasmic domain), residues 36-56 (helical transmembrane domain) and residues 57-233 (extracellular domain). A fragment (e.g., a peptide or an epitope) of a TNF protein is less than the length of the full length protein, e.g., a fragment is at least 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 200 or more residues in length, but less than e.g., 233 residues in the case of TNF above.

The human TNF nucleic acid sequence is provided below and is incorporated herein by reference (start and stop codons are underlined; NCBI GenBank: NM_000594.4).

SEQ ID NO: 523 1 agcagacgct ccctcagcaa ggacagcaga ggaccagcta agagggagag aagcaactac 61 agaccccccc tgaaaacaac cctcagacgc cacatcccct gacaagctgc caggcaggtt 121 ctcttcctct cacatactga cccacggctc caccctctct cccctggaaa ggacacc atg 181 agcactgaaa gcatgatccg ggacgtggag ctggccgagg aggcgctccc caagaagaca 241 ggggggcccc agggctccag gcggtgcttg ttcctcagcc tcttctcctt cctgatcgtg 301 gcaggcgcca ccacgctctt ctgcctgctg cactttggag tgatcggccc ccagagggaa 361 gagttcccca gggacctctc tctaatcagc cctctggccc aggcagtcag atcatcttct 421 cgaaccccga gtgacaagcc tgtagcccat gttgtagcaa accctcaagc tgaggggcag 481 ctccagtggc tgaaccgccg ggccaatgcc ctcctggcca atggcgtgga gctgagagat 541 aaccagctgg tggtgccatc agagggcctg tacctcatct actcccaggt cctcttcaag 601 ggccaaggct gcccctccac ccatgtgctc ctcacccaca ccatcagccg catcgccgtc 661 tcctaccaga ccaaggtcaa cctcctctct gccatcaaga gcccctgcca gagggagacc 721 ccagaggggg ctgaggccaa gccctggtat gagcccatct atctgggagg ggtcttccag 781 ctggagaagg gtgaccgact cagcgctgag atcaatcggc ccgactatct cgactttgcc 841 gagtctgggc aggtctactt tgggatcatt gccctg tga g gaggacgaac atccaacctt 901 cccaaacgcc tcccctgccc caatcccttt attaccccct ccttcagaca ccctcaacct 961 cttctggctc aaaaagagaa ttgggggctt agggtcggaa cccaagctta gaactttaag 1021 caacaagacc accacttcga aacctgggat tcaggaatgt gtggcctgca cagtgaagtg 1081 ctggcaacca ctaagaattc aaactggggc ctccagaact cactggggcc tacagctttg 1141 atccctgaca tctggaatct ggagaccagg gagcctttgg ttctggccag aatgctgcag 1201 gacttgagaa gacctcacct agaaattgac acaagtggac cttaggcctt cctctctcca 1261 gatgtttcca gacttccttg agacacggag cccagccctc cccatggagc cagctccctc 1321 tatttatgtt tgcacttgtg attatttatt atttatttat tatttattta tttacagatg 1381 aatgtattta tttgggagac cggggtatcc tgggggaccc aatgtaggag ctgccttggc 1441 tcagacatgt tttccgtgaa aacggagctg aacaataggc tgttcccatg tagccccctg 1501 gcctctgtgc cttcttttga ttatgttttt taaaatattt atctgattaa gttgtctaaa 1561 caatgctgat ttggtgacca actgtcactc attgctgagc ctctgctccc caggggagtt 1621 gtgtctgtaa tcgccctact attcagtggc gagaaataaa gtttgcttag aaaagaaa

Exemplary landmark residues, domains, and fragments of TNF include, but are not limited to residues 280-285 (TNF domain), or residues 458-1678 (exon).

The human amino acid sequence of IL-2 is provided below and is incorporated herein by reference (NCBI GenBank NP 000577.1 or UniProt P60568)

(SEQ ID NO:   )   1 myrmqllsci alslalvtns aptssstkkt qlqlehllld lqmilnginn yknpkltrml  61 tfkfympkka telkhlqcle eelkpleevl nlaqsknfhl rprdlisnin vivlelkgse 121 ttfmceyade tativeflnr witfcqsiis tlt

Exemplary landmark residues, domains, and fragments of IL-2 include, but are not limited to residues 1-20 (signal peptide), residues 21-153 (mature peptide), or residue 23 (glycosylation site). A fragment (e.g., a peptide or an epitope) of a IL-2 protein is less than the length of the full length protein, e.g., a fragment is at least 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 153 or more residues in length, but less than e.g., 153 residues in the case of IL-2 above.

The human IL-2 nucleic acid sequence is provided below and is incorporated herein by reference (start and stop codons are underlined; NCBI GenBank: NM_000586.4).

1 ctatcaccta agtgtgggct aatgtaacaa agagggattt cacctacatc cattcagtca 61 gtctttgggg gtttaaagaa attccaaaga gtcatcagaa gaggaaaaat gaaggtaatg 121 ttttttcaga caggtaaagt ctttgaaaat atgtgtaata tgtaaaacat tttgacaccc 181 ccataatatt tttccagaat taacagtata aattgcatct cttgttcaag agttccctat 241 cactctcttt aatcactact cacagtaacc tcaactcctg ccaca atg ta caggatgcaa 301 ctcctgtctt gcattgcact aagtcttgca cttgtcacaa acagtgcacc tacttcaagt 361 tctacaaaga aaacacagct acaactggag catttactgc tggatttaca gatgattttg 421 aatggaatta ataattacaa gaatcccaaa ctcaccagga tgctcacatt taagttttac 481 atgcccaaga aggccacaga actgaaacat cttcagtgtc tagaagaaga actcaaacct 541 ctggaggaag tgctaaattt agctcaaagc aaaaactttc acttaagacc cagggactta 601 atcagcaata tcaacgtaat agttctggaa ctaaagggat ctgaaacaac attcatgtgt 661 gaatatgctg atgagacagc aaccattgta gaatttctga acagatggat taccttttgt 721 caaagcatca tctcaacact gact tga taa ttaagtgctt cccacttaaa acatatcagg 781 ccttctattt atttaaatat ttaaatttta tatttattgt tgaatgtatg gtttgctacc 841 tattgtaact attattctta atcttaaaac tataaatatg gatcttttat gattcttttt 901 gtaagcccta ggggctctaa aatggtttca cttatttatc ccaaaatatt tattattatg 961 ttgaatgtta aatatagtat ctatgtagat tggttagtaa aactatttaa taaatttgat 1021 aaatataaa

Exemplary landmark residues, domains, and fragments of IL-2 include, but are not limited to residues 286-345 (signal peptide), residues 346-744 (mature peptide), or 286-747 (coding region).

The human amino acid sequence of IL-6 is provided below and is incorporated herein by reference (NCBI GenBank NP_000591.1 or UniProt P05231).

(SEQ ID NO:   ) 1 mnsfstsafg pvafslglll vlpaafpapv ppgedskdva aphrqpltss eridkqiryi 61 ldgisalrke tcnksnmces skealaennl nlpkmaekdg cfqsgfneet clvkiitgll 121 efevyleylq nrfesseeqa ravqmstkvl iqflqkkakn ldaittpdpt tnaslltklq 181 aqnqwlqdmt thlilrsfke flqsslralr qm

Exemplary landmark residues, domains, and fragments of IL-6 include, but are not limited to residues 1-29 (signal peptide), residues 30-212 (mature peptide), or residue 73 (glycosylation site). A fragment (e.g., a peptide or an epitope) of a IL-6 protein is less than the length of the full length protein, e.g., a fragment is at least 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 200 or more residues in length, but less than e.g., 212 residues in the case of IL-6 above.

The human IL-6 nucleic acid sequence is provided below and is incorporated herein by reference (start and stop codons are underlined; NCBI GenBank: NM_000600.5).

(SEQ ID NO:   ) 1 attctgccct cgagcccacc gggaacgaaa gagaagctct atctcccctc caggagccca 61 gct atg aact ccttctccac aagcgccttc ggtccagttg ccttctccct ggggctgctc 121 ctggtgttgc ctgctgcctt ccctgcccca gtacccccag gagaagattc caaagatgta 181 gccgccccac acagacagcc actcacctct tcagaacgaa ttgacaaaca aattcggtac 241 atcctcgacg gcatctcagc cctgagaaag gagacatgta acaagagtaa catgtgtgaa 301 agcagcaaag aggcactggc agaaaacaac ctgaaccttc caaagatggc tgaaaaagat 361 ggatgcttcc aatctggatt caatgaggag acttgcctgg tgaaaatcat cactggtctt 421 ttggagtttg aggtatacct agagtacctc cagaacagat ttgagagtag tgaggaacaa 481 gccagagctg tgcagatgag tacaaaagtc ctgatccagt tcctgcagaa aaaggcaaag 541 aatctagatg caataaccac ccctgaccca accacaaatg ccagcctgct gacgaagctg 601 caggcacaga accagtggct gcaggacatg acaactcatc tcattctgcg cagctttaag 661 gagttcctgc agtccagcct gagggctctt cggcaaatg t ag catgggca cctcagattg 721 ttgttgttaa tgggcattcc ttcttctggt cagaaacctg tccactgggc acagaactta 781 tgttgttctc tatggagaac taaaagtatg agcgttagga cactatttta attattttta 841 atttattaat atttaaatat gtgaagctga gttaatttat gtaagtcata tttatatttt 901 taagaagtac cacttgaaac attttatgta ttagttttga aataataatg gaaagtggct 961 atgcagtttg aatatccttt gtttcagagc cagatcattt cttggaaagt gtaggcttac 1021  ctcaaataaa tggctaactt atacatattt ttaaagaaat atttatattg tatttatata 1081  atgtataaat ggtttttata ccaataaatg gcattttaaa aaattca

Exemplary landmark residues, domains, and fragments of IL-6 include, but are not limited to residues 64-150 (signal peptide), residues 151-699 (mature peptide), or 64-702 (coding region).

The human amino acid sequence of IL-7 is provided below and is incorporated herein by reference (NCBI GenBank NP_000871.1 or UniProt P13232)

(SEQ ID NO:       )   1 mfhvsfryif glpplilvll pvassdcdie gkdgkqyesv lmvsidqlld smkeigsncl  61 nnefnffkrh icdankegmf lfraarklrq flkmnstgdf dlhllkvseg ttillnctgq 121 vkgrkpaalg eaqptkslee nkslkeqkkl ndlcflkrll qeiktcwnki lmgtkeh

Exemplary landmark residues, domains, and fragments of IL-7 include, but are not limited to residues 1-25 (signal peptide), residues 26-177 (mature peptide), or residue 95 (glycosylation site). A fragment (e.g., a peptide or an epitope) of a IL-7 protein is less than the length of the full length protein, e.g., a fragment is at least 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 150 or more residues in length, but less than e.g., 177 residues in the case of IL-7 above.

The human IL-7 nucleic acid sequence is provided below and is incorporated herein by reference (start and stop codons are underlined; NCBI GenBank: NM_000880.4).

   1 acacttgtgg cttccgtgca cacattaaca actcatggtt ctagctccca gtcgccaagc   61 gttgccaagg cgttgagaga tcatctggga agtcttttac ccagaattgc tttgattcag  121 gccagctggt ttttcctgcg gtgattcgga aattcgcgaa ttcctctggt cctcatccag  181 gtgcgcggga agcaggtgcc caggagagag gggataatga agattccatg ctgatgatcc  241 caaagattga acctgcagac caagcgcaaa gtagaaactg aaagtacact gctggcggat  301 cctacggaag ttatggaaaa ggcaaagcgc agagccacgc cgtagtgtgt gccgcccccc  361 ttgggatgga tgaaactgca gtcgcggcgt gggtaagagg aaccagctgc agagatcacc  421 ctgcccaaca cagactcggc aactccgcgg aagaccaggg tcctgggagt gactatgggc  481 ggtgagagct tgctcctgct ccagttgcgg tcatcatgac tacgcccgcc tcccgcagac  541 c atg ttccat gtttctttta ggtatatctt tggacttcct cccctgatcc ttgttctgtt  601 gccagtagca tcatctgatt gtgatattga aggtaaagat ggcaaacaat atgagagtgt  661 tctaatggtc agcatcgatc aattattgga cagcatgaaa gaaattggta gcaattgcct  721 gaataatgaa tttaactttt ttaaaagaca tatctgtgat gctaataagg aaggtatgtt  781 tttattccgt gctgctcgca agttgaggca atttcttaaa atgaatagca ctggtgattt  841 tgatctccac ttattaaaag tttcagaagg cacaacaata ctgttgaact gcactggcca  901 ggttaaagga agaaaaccag ctgccctggg tgaagcccaa ccaacaaaga gtttggaaga  961 aaataaatct ttaaaggaac agaaaaaact gaatgacttg tgtttcctaa agagactatt 1021 acaagagata aaaacttgtt ggaataaaat tttgatgggc actaaagaac ac tga aaaat 1081 atggagtggc aatatagaaa cacgaacttt agctgcatcc tccaagaatc tatctgctta 1141 tgcagttttt cagagtggaa tgcttcctag aagttactga atgcaccatg gtcaaaacgg 1201 attagggcat ttgagaaatg catattgtat tactagaaga tgaatacaaa caatggaaac 1261 tgaatgctcc agtcaacaaa ctatttctta tatatgtgaa catttatcaa tcagtataat 1321 tctgtactga tttttgtaag acaatccatg taaggtatca gttgcaataa tacttctcaa 1381 acctgtttaa atatttcaag acattaaatc tatgaagtat ataatggttt caaagattca 1441 aaattgacat tgctttactg tcaaaataat tttatggctc actatgaatc tattatactg 1501 tattaagagt gaaaattgtc ttcttctgtg ctggagatgt tttagagtta acaatgatat 1561 atggataatg ccggtgagaa taagagagtc ataaacctta agtaagcaac agcataacaa 1621 ggtccaagat acctaaaaga gatttcaaga gatttaatta atcatgaatg tgtaacacag 1681 tgccttcaat aaatggtata gcaaatgttt tgacatgaaa aaaggacaat ttcaaaaaaa 1741 taaaataaaa taaaaataaa ttcacctagt ctaaggatgc taaaccttag tactgagtta 1801 cattgtcatt tatatagatt ataacttgtc taaataagtt tgcaatttgg gagatatatt 1861 tttaagataa taatatatgt ttacctttta attaatgaaa tatctgtatt taattttgac 1921 actatatctg tatataaaat attttcatac agcattacaa attgcttact ttggaataca 1981 tttctccttt gataaaataa atgagctatg tattaa

Exemplary landmark residues, domains, and fragments of IL-7 include, but are not limited to residues 542-616 (signal peptide), residues 617-1072 (mature peptide), or 542-1075 (coding region).

The human amino acid sequence of IL-12 alpha subunit is provided below and is incorporated herein by reference (UniProt P29459).

(SEQ ID NO: 493)   1 mcparsllly atlvlldhls larnlpvatp dpgmfpclhh sqnllravsn mlqkarqtle  61 fypctseeid heditkdkts tveaclplel tknesclnsr etsfitngsc lasrktsfmm 121 alclssiyed lkmyqvefkt mnakllmdpk rqifldqnml avidelmqal nfnsetvpqk 181 ssleepdfyk tkiklcillh afriravtid rvmsylnas

Exemplary landmark residues, domains, and fragments of IL-12 alpha subunit include, but are not limited to residues 1-22 (signal peptide) or residues 23-219 (mature peptide). A fragment (e.g., a peptide or an epitope) of a IL-12 protein is less than the length of the full length protein, e.g., a fragment is at least 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 200 or more residues in length, but less than e.g., 219 residues in the case of IL-12 above.

The human IL-12 sununit alpha nucleic acid sequence is provided below and is incorporated herein by reference (start and stop codons are underlined; NCBI GenBank: AF101062.1).

(SEQ ID NO:    )   1 atg tggcccc ctgggtcagc ctcccagcca ccgccctcac ctgccgcggc cacaggtctg  61 catccagcgg ctcgccctgt gtccctgcag tgccggctca gcatgtgtcc agcgcgcagc 121 ctcctccttg tggctaccct ggtcctcctg gaccacctca gtttggccag aaacctcccc 181 gtggccactc cagacccagg aatgttccca tgccttcacc actcccaaaa cctgctgagg 241 gccgtcagca acatgctcca gaaggccaga caaactctag aattttaccc ttgcacttct 301 gaagagattg atcatgaaga tatcacaaaa gataaaacca gcacagtgga ggcctgttta 361 ccattggaat taaccaagaa tgagagttgc ctaaattcca gagagacctc tttcataact 421 aatgggagtt gcctggcctc cagaaagacc tcttttatga tggccctgtg ccttagtagt 481 atttatgaag acttgaagat gtaccaggtg gagttcaaga ccatgaatgc aaagcttctg 541 atggatccta agaggcagat ctttctagat caaaacatgc tggcagttat tgatgagctg 601 atgcaggccc tgaatttcaa cagtgagact gtgccacaaa aatcctccct tgaagaaccg 661 gatttttata aaactaaaat caagctctgc atacttcttc atgctttcag aattcgggca 721 gtgactattg atagagtgat gagctatctg aatgcttcc t aa

Exemplary landmark residues, domains, and fragments of IL-12 alpha subunit include, but are not limited to residues 1-762 (coding region), or residues 1-203 (interleukin binding region).

The human amino acid sequence of IL-12 beta subunit is provided below and is incorporated herein by reference (UniProt P29460).

(SEQ ID NO: 524)   1 mchgqlvisw fslvflaspl vaiwelkkdv yvveldwypd apgemvvltc dtpeedgitw  61 tldqssevlg sqktltiqvk efgdagqytc hkggevlshs llllhkkedg iwstdilkdq 121 kepknktflr ceaknysgrf tcwwlttist dltfsvkssr gssdpqgvtc gaatlsaerv 181 rgdnkeyeys vecqedsacp aaeeslpiev mvdavhklky enytssffir diikpdppkn 241 lqlkplknsr qvevsweypd twstphsyfs ltfcvqvqgk skrekkdrvf tdktsatvic 301 rknasisvra qdryysssws ewasvpcs

Exemplary landmark residues, domains, and fragments of IL-12 beta subunit include, but are not limited to residues 1-22 (signal peptide) or residues 23-328 (mature peptide). A fragment (e.g., a peptide or an epitope) of a IL-12 beta subunit protein is less than the length of the full length protein, e.g., a fragment is at least 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 200 or more residues in length, but less than e.g., 328 residues in the case of IL-12 beta subunit above.

The human IL-12 subunit beta nucleic acid sequence is provided below and is incorporated herein by reference (stop and start codons are bold and underlined NM_002187.3).

SEQ ID NO: 525    1 agaagaaaca acatctgttt cagggccatt ggactctccg tcctgcccag agcaag atg t   61 gtcaccagca gttggtcatc tcttggtttt ccctggtttt tctggcatct cccctcgtgg  121 ccatatggga actgaagaaa gatgtttatg tcgtagaatt ggattggtat ccggatgccc  181 ctggagaaat ggtggtcctc acctgtgaca cccctgaaga agatggtatc acctggacct  241 tggaccagag cagtgaggtc ttaggctctg gcaaaaccct gaccatccaa gtcaaagagt  301 ttggagatgc tggccagtac acctgtcaca aaggaggcga ggttctaagc cattcgctcc  361 tgctgcttca caaaaaggaa gatggaattt ggtccactga tattttaaag gaccagaaag  421 aacccaaaaa taagaccttt ctaagatgcg aggccaagaa ttattctgga cgtttcacct  481 gctggtggct gacgacaatc agtactgatt tgacattcag tgtcaaaagc agcagaggct  541 cttctgaccc ccaaggggtg acgtgcggag ctgctacact ctctgcagag agagtcagag  601 gggacaacaa ggagtatgag tactcagtgg agtgccagga ggacagtgcc tgcccagctg  661 ctgaggagag tctgcccatt gaggtcatgg tggatgccgt tcacaagctc aagtatgaaa  721 actacaccag cagcttcttc atcagggaca tcatcaaacc tgacccaccc aagaacttgc  781 agctgaagcc attaaagaat tctcggcagg tggaggtcag ctgggagtac cctgacacct  841 ggagtactcc acattcctac ttctccctga cattctgcgt tcaggtccag ggcaagagca  901 agagagaaaa gaaagataga gtcttcacgg acaagacctc agccacggtc atctgccgca  961 aaaatgccag cattagcgtg cgggcccagg accgctacta tagctcatct tggagcgaat 1021 gggcatctgt gccctgcagt  tag gttctga tccaggatga aaatttggag gaaaagtgga 1081 agatattaag caaaatgttt aaagacacaa cggaatagac ccaaaaagat aatttctatc 1141 tgatttgctt taaaacgttt ttttaggatc acaatgatat ctttgctgta tttgtatagt 1201 tagatgctaa atgctcattg aaacaatcag ctaatttatg tatagatttt ccagctctca 1261 agttgccatg ggccttcatg ctatttaaat atttaagtaa tttatgtatt tattagtata 1321 ttactgttat ttaacgtttg tctgccagga tgtatggaat gtttcatact cttatgacct 1381 gatccatcag gatcagtccc tattatgcaa aatgtgaatt taattttatt tgtactgaca 1441 acttttcaag caaggctgca agtacatcag ttttatgaca atcaggaaga atgcagtgtt 1501 ctgataccag tgccatcata cacttgtgat ggatgggaac gcaagagata cttacatgga 1561 aacctgacaa tgcaaacctg ttgagaagat ccaggagaac aagatgctag ttcccatgtc 1621 tgtgaagact tcctggagat ggtgttgata aagcaattta gggccactta cacttctaag 1681 caagtttaat ctttggatgc ctgaatttta aaagggctag aaaaaaatga ttgaccagcc 1741 tgggaaacat aacaagaccc cgtctctaca aaaaaaattt aaaattagcc aggcgtggtg 1801 gctcatgctt gtggtcccag ctgttcagga ggatgaggca ggaggatctc ttgagcccag 1861 gaggtcaagg ctatggtgag ccgtgattgt gccactgcat accagcctag gtgacagaat 1921 gagaccctgt ctcaaaaaaa aaaatgattg aaattaaaat tcagctttag cttccatggc 1981 agtcctcacc cccacctctc taaaagacac aggaggatga cacagaaaca ccgtaagtgt 2041 ctggaaggca aaaagatctt aagattcaag agagaggaca agtagttatg gctaaggaca 2101 tgaaattgtc agaatggcag gtggcttctt aacagccctg tgagaagcag acagatgcaa 2161 agaaaatctg gaatcccttt ctcattagca tgaatgaacc tgatacacaa ttatgaccag 2221 aaaatatggc tccatgaagg tgctactttt aagtaatgta tgtgcgctct gtaaagtgat 2281 tacatttgtt tcctgtttgt ttatttattt atttattttt gcattctgag gctgaactaa 2341 taaaaactct tctttgtaat cata

Exemplary landmark residues, domains, and fragments of IL-12 beta subunit include, but are not limited to residues 57-122 (signal peptide), or residues 123-1040 (mature protein).

In other aspects of the invention, the methods described herein comprise administering a pHLIP® construct comprising an antibody recruiting molecule that is linked to one or more pHLIP® peptides. For example, the antibody recruiting molecule comprises an epitope, including for example a small molecule (alternatively, a “small molecule antigen”). For example, the small molecule epitope comprises a Di-nitrophenyl (DNP) group, or a derivative thereof. As used herein, the terms “DNP” and “2,4-DNP” interchangeably refer to 2,4-dinitrophenol, a salt, solvate or adduct thereof.

In examples, the small molecule epitope comprises O-(2,4-dinitrophenyl)hydroxylamine (structure provided below):

In embodiments, the composition of the present disclosure includes modified DNPs, such as those conjugated to polyethylene glycol may be used in the present disclosure. The DNP, DNP derivative, or salt in the composition of the present disclosure may have a molecular weight in the range from 200 Da to 1,000 Da or from 200 Da to 500 Da.

In some examples, the DNP derivative may be substituted, e.g., with an alkyl group, an alkylene group, a heteroalkyl group, a cycloalkyl group, an aryl group, or any combination thereof.

Also within the invention is a composition comprising an antibody or immune cell recruiting molecule linked to one or more pHLIP® peptides by a non-cleavable linker compound for eliciting an anti-tumor response in a subject. Also provided herein are methods for promoting an immune response. For example, the method comprises administering a composition comprises an epitope comprising at least 4 amino acids conjugated to a pHLIP® peptide. The pHLIP® peptide positions an epitope on the surface of the targeted cells in diseased tissue to induce an immune response predominantly in diseased tissue. For example, if the epitope is a peptide, it can be added as an extension of the non-inserting end of the pHLIP peptide. Furthermore, the epitope then interacts with endogenous or exogenous immune cells, endogenous antibodies and proteins, e.g., pre-existing antibodies and proteins in the subject's body, or exogenous antibodies administrated into body, or antibodies generated in the course of vaccination, which then induce an immune response. Also provided herein are methods for promoting delivery of cytotoxic payloads with ADCs to induce cell killing. Furthermore, the epitope interacts with ADCs administrated into body, which then induce cell killing.

Furthermore, provided herein are methods of treating a diseased tissue with a naturally acidic extracellular environment or a tissue with an artificially induced acidic extracellular environment relative to normal physiological pH in a subject. For example, the diseased tissue includes a cancerous tissue or a tumor. As described above, the composition recruits the subject's immune cells, endogenous antibodies and proteins to induce an immune response, and thereby treats the diseased tissue in the subject. The immune response can include, for example, initiation of complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), or the release of cytokines or inflammatory mediators to promote T-cell or NK-cell responses. The immune response can include, for example, homing of T-cells and NK-cells and their activation. Also as described above, the composition promotes binding of antibody-drug conjugates to the cells in targeted tissue, and thus promotes cell killing.

Also within the invention is a method of augmenting (increasing) an immune response in a subject, comprising administering to the subject a composition comprising an epitope linked to a pHLIP® peptide as described above. In some examples, the composition is administered using methods well known in the art, e.g., the composition is injected directly into a tumor mass. Alternatively, the composition is systemically administered.

Formulations provided herein may include an Epitope-Linker-Peptide, where “Peptide” is a pHLIP® peptide. The formulation may be suitable for intravenous, subcutaneous, intraarterial, intraperitoneal, intracerebral, intracerebroventricular, intrathecal, intracardiac, intracavernous, intraosseous, intraocular, or intravitreal administration are also provided. In some examples, a formulation is used for intramuscular, intradermal, transdermal, transmucosal, intralesional, subcutaneous, topical, epicutaneous, extra-amniotic, intravaginal, intravesical, nasal, or oral administration. The present subject matter also includes a formulation for intravesical instillation. In some embodiments, the formulation is used for the treatment of cancer (e.g., solid tumors).

Also provided herein is a formulation comprising an Epitope-Linker-Peptide that comprises multiple pHLIP® peptides, e.g., for systemic administration. Also provided herein is a formulation comprising an Epitope-Linker-Peptide that comprises multiple epitopes, e.g., for systemic administration. In certain embodiments, the formulation is used for the treatment of cancer or diseases associated with inflammation.

Provided herein is a method of treating cancer or inflammation in a subject, comprising administering to the subject an effective amount of a pH-triggered compound (a pHLIP® peptide) linked to an epitope (a “pHLIP® construct”), which is then delivered by pHLIP® to the surface of the cell. For example, the cancer includes a solid tumor. Non-limiting examples of cancer include colon cancer, prostate cancer, breast cancer, bladder cancer, lung cancer, skin cancer, liver cancer, bone cancer, ovarian cancer, stomach cancer, pancreatic cancer, testicular cancer, and brain cancer.

Systemic or blood-borne tumor cells, e.g., cancers of the circulatory system, may also be treated using the pHLIP® peptide constructs.

The composition preferentially targets a diseased tissue compared to a healthy tissue, thereby minimizing damage to the healthy tissue. For example, the composition selectively promotes cell killing in the diseased tissue, e.g., the tumor cell.

Included herein are pharmaceutical compositions comprising a pH-triggered peptide linked to an epitope and a pharmaceutically acceptable carrier.

As used herein, “effective” when referring to an amount of a compound refers to the quantity of the compound that is sufficient to yield a desired response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this disclosure.

In some embodiments, a subject is a mammal. In certain embodiments, the mammal is a rodent (e.g., a mouse or a rat), a primate (e.g., a chimpanzee, a gorilla, a monkey, a gibbon, a baboon), a cow, a camel, a dog, a cat, a horse, a llama, a sheep, a goat, or a pig. In preferred embodiments, the subject is a human.

In some examples, the exogenous cells or monoclonal antibody or antibody-drug conjugate is administered to the subject during or after administration of the epitope pHLIP® peptide construct. In some examples, the subject comprises endogenous, e.g., pre-existing, antibodies or immune cells to the epitope of the pHLIP® peptide construct. Alternatively, the subject does not comprise existing antibodies to the epitope delivered by the construct (at the time of initial administration). In such examples, a subject may be immunized with the epitope to generate an antibody response and then the subject is subsequently administered the pHLIP®-epitope construct. In such examples, the construct is administered after administration of the antigen epitope in a form that is not conjugated to a pHLIP®.

Each embodiment disclosed herein is contemplated as being applicable to each of the other disclosed embodiments. Thus, all combinations of the various elements described herein are within the scope of the invention.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below.

DESCRIPTION OF THE DRAWINGS

FIG. 1 is a diagram of a pHLIP® construct in which an epitope is linked to a pHLIP® peptide.

FIG. 2A is a diagram of a pHLIP® construct in which multiple epitopes are linked to a single pHLIP® peptide.

FIG. 2B is a diagram of pHLIP® construct in which two epitopes are linked to a single pHLIP® peptide.

FIG. 3 is a diagram of a pHLIP® construct in which an epitope is linked to multiple pHLIP® peptides.

FIG. 4 is a diagram of a pHLIP® construct in which multiple epitopes are linked to multiple pHLIP® peptides.

FIG. 5A is a schematic presentation of epitope tethered to the surface of cell by pHLIP®. As a result, the targeted cell becomes decorated with epitopes and endogenous (natural) antibodies, exogenous antibodies, ADCs administrated into body, antibodies which are produced (generated) in the course of vaccination, and bind the targeted cell to promote cell killing.

FIG. 5B is a schematic presentation of two epitopes tethered to the surface of cell by pHLIP® to bind two heads of one antibody molecule. As a result, the targeted cell becomes decorated with epitopes and endogenous (natural) antibodies, or exogenous antibodies, or ADCs administrated into body, or antibodies, which are produced (generated) in the course of vaccination bind targeted cell to promote cell killing.

FIG. 6 depict fluorescent (647 nm) images obtained on tumor spheroids treated with an anti-DNP fluorescent antibody, DAPI, or an anti-DNP fluorescent antibody pre-mixed with DNP-PEG12-pHLIP® construct followed by washing and imaging (upper raw), and treated with DNP-pHLIP®, DNP-PEG4-pHLIP® or DNP-PEG12-pHLIP® first, washed, and then treated with anti-DNP fluorescent antibody followed by washing and imaging of spheroids (bottom raw).

FIG. 7 depict fluorescent images obtained on tumor spheroids treated with DNP-PEG12-pHLIP® first, washed, and then treated with anti-DNP fluorescent antibody and DAPI, washing and imaging of tumor spheroids at different channels using an inverted confocal microscope and 40× objective.

FIG. 8 depicts a representative overlay of fluorescent and brightfield images of tumor spheroids treated with DNP-PEG12-pHLIP®, washed, then treated with anti-DNP antibody or IgM followed by addition of human serum with active complement and PI fluorescent dye, followed by washing and imaging. The images were obtained 2 hours after the treatment.

DETAILED DESCRIPTION

The invention features compositions and methods for decorating target cells (cancer cells) using epitope-pHLIP® compounds, such that the pHLIP® targets tumors by responding to cell surface acidity, inserting into cancer cell membranes, and locating (positioning) a specified epitope on the cell surface to induce cell killing.

Epitopes bind and/or attract exogenous immune cells (T-cells or NK-cells) or exogenously developed monoclonal antibodies or antibody-drug conjugates administrated into body during or after of epitope-pHLIP® compound administration, and selectively promote cell killing while sparing normal tissues. Among these epitopes include epitopes for developed monoclonal antibodies.

Epitopes bind and/or attract endogenous (natural) immune cells (lymphocytes) or endogenous antibodies already present in the blood, and selectively initiate a specific immune response to attack the tumor while sparing normal tissues. Among these epitopes are epitopes associated with the surfaces of animal cells and bacteria. In many cases, humans already have developed antibodies in blood stream, which recognize such epitopes. Epitopes delivered according to the methods described herein may also bind/attract endogenous antibodies, which are produced (generated) in the course of vaccination. The epitopes (any antigen molecule used for vaccination), is linked (conjugated) to a pHLIP® peptide and delivered to tumors to promote an immune reaction within target tissue, e.g., by using harnessing influenza vaccines that create antibodies to virus surface epitopes. In some examples, an individual is immunized using a chosen antigen, followed by targeting the antigen targeted to tumor cells by a pHLIP® peptide.

Decorated Acidic Diseased Cells

Acidic diseased cells, e.g., cancer cells are targeted using epitope-pHLIP® peptide compositions, such that the pHLIP® peptide targets tumors by responding to cell surface acidity, inserting into cancer cell membranes, and locating/positioning a specific epitope on the cell surface to induce and promote cellular responses including immune stimulation and inhibition of cell proliferation. The immune stimulation leads to cytotoxicity and death of the acidic disease cell.

Epitope-pHLIP® Peptide Compositions

Representations of exemplary pHLIP® compositions for therapeutic use are shown in FIGS. 1-4. The compositions comprise a pHLIP® peptide (or pHLIP® conjugate, where the pHLIP® peptide is linked to an epitope for delivery/positioning on the surface of diseased cells). pHLIP® peptides are described here and in U.S. Pat. Nos. 9,814,781 and 9,289,508 (hereby incorporated by reference) as well as U.S. Patent Publication 20180117183, 20180064648, 20180221500, 20180117183, 20180064648, 20160256560, 20150191508, 20150051153, and 20120142042, 20120039990, 20080233107, as well as PCT Application No. PCT/US2017/023458 (cyclic pHLIP® peptides), each of which is hereby incorporated by reference.

FIG. 1 shows a construct in which an epitope is linked to a pHLIP® peptide.

FIGS. 2A and 2B show a construct in which multiple epitopes are linked to a single pHLIP® peptide.

FIG. 3 shows a construct in which an epitope is linked to multiple pHLIP® peptides.

FIG. 4 shows a construct in which multiple epitopes are linked to multiple pHLIP® peptides.

An exemplary composition comprises the following formula:

Epitope-Linker-Peptide

The “Epitope” may include a peptide, a protein or a fragment thereof, or a small molecule such as an organic molecule, to induce an immune response or promote cell killing by attracting endogenous (pre-existing) immune cells or antibodies, exogenous (administered as in passive antibody-based immunotherapy) engineered immune cells or purified antibodies, ADCs administrated into humans, or antibodies generated in the course of vaccination.

“Peptide” is a pHLIP® peptide (a non-limiting example is a pHLIP® peptide comprising the sequence AXDDQNPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: 18) or AXDQDNPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______), where “X” is a functional group, e.g., for conjugation purposes, selected from a lysine (Lys), a cysteine (Cys), or an Azido-containing amino acid. In some cases “Peptide” is a pHLIP® conjugate, where the pHLIP® peptide is linked with a drug molecule for intracellular delivery.

“Linker” comprises a covalent bond, or a chemical linker, or an extension of the membrane non-inserting flanking region of pHLIP® peptide. If the epitope is a peptide or protein, it may be constructed as an extension of the pHLIP® peptide, and no linker may be required. Non-limiting example of linker is a polyethylene glycol (PEG) polymer in size from 200 Da to 20 kDa. Non-limiting example of an extension is a poly-Glycine polypeptide. Epitope(s) are also linked to pHLIP® peptide(s) via non-cleavable link(s).

Non-limiting examples of a Linker is a mucin domain, which is a high molecular weight, heavily glycosylated protein (glycoconjugate) produced by epithelial tissues in most humans. In other examples, the linker may include biopolymers, including, for example cellulose, starch or chitin.

An exemplary composition comprises the following formula:

Epitope₂-Linker₂-Pept

The “Epitope” comprises a peptide, a protein or a fragment thereof, or a small molecule such as an organic molecule, to induce an immune response or promote cell killing by attracting endogenous (pre-existing) immune cells or antibodies, exogenous (administered as in passive antibody-based immunotherapy) engineered T-cells or NK-cells or purified antibodies, ADCs administrated into humans, or antibodies generated as a result of vaccination.

“Peptide” is a pHLIP® peptide comprising the sequence: AX(Z)_(n)XPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______), wherein upper case “X” indicates any amino acid residue, and can include a lysine (Lys), a cysteine (Cys), or an Azido-containing amino acid. The X may be used for conjugation to another moiety. The “Z” indicates any amino acid residue, and n can be any integer between and including 1-10 (e.g., 1≤n≤10). For example, (Z)_(n) may be QDNDQN (SEQ ID NO: ______) or any combination of polar amino acid residues including D, E, N or Q.

A compound is characterized as polar if it has a log P of less than −0.4. The epitope compound may be moderately hydrophobic. Polar: LogP<−0.4; Moderately hydrophobic: 2.5<LogP<−0.4; and Hydrophobic: LogP>2.5. The polarity and/or hydrophobicity of an epitope is measured using methods known in the art, e.g., by determining LogP, in which P is the octanol-water partition coefficient. A substance is dissolved into an octanol-water mixture, mixed, and allowed to come to equilibration. The amount of substance in each (or one) phases is then measured. The measurements itself could be in a number of ways known in the art, e.g., by measuring absorbance, or determining the amount using NMR, HPLC, or other known methods. As described herein, moderately hydrophobic, for example, is defined as molecule with LogP value in the range of 2.5 to −0.4, there are a lot of examples.

Linker is a linker, wherein the linker is a polyethylene glycol, PEG. For example, the formula PEG_(m), includes that “m” may be any integer between and including 12 and 24 (e.g., 12≤m≤PEG12-24 polymer). Each “—” may be a covalent bond.

When an epitope is conjugated to the pHLIP® peptide via a PEG12-24 linker and 6-8 residues are positioned between epitope-PEG attachments to the pHLIP® peptide, the distance between epitopes can be in the range of 5-25 nm. Alternatively, the distance may be about 10 nm, or 10-15 nm, which corresponds to a typical distance between the two antigen binding sites binding sites of an antibody.

The pHLIP® compositions described are used for decoration of cells in targeted acidic tissue to elicit an immune response or promote delivery of cytotoxic payload by ADCs to kill the diseased cells or tissue.

Non-limiting examples of epitopes are the following:

Peptide Epitope-pHLIP® Peptide Compositions

Peptide antigens, e.g., peptides less than 50 amino acid residues in length, e.g., peptide antigens greater than 5 and less than 20, less than 15, less than 10, or less than 8 amino acid residues.

HER2 (Also Referred to as Receptor Tyrosine-Protein Kinase erbB-2 or Human Epidermal Growth Factor 2)

The HER family of transmembrane tyrosine kinase receptors are composed of four members, BER1 to HER4. HER2 is a ligand-orphan receptor expressed in many human tumors and overexpressed in 25-30% of breast cancers. HER2 amplifies the signal provided by other receptors of the HER family by forming heterodimers. The role of HER2 in the HER signaling network led to the development of anti-HER2 monoclonal antibodies (MAbs) for cancer therapy. In particular, the humanized MAb trastuzumab (Herceptin) or Herceptin-drug conjugates have antitumor activity against HER2-overexpressing human breast tumor cells and are widely used for the treatment of women with HER2 overexpressing breast cancers. One of the primary effects of trastuzumab is to induce antibody-dependent cellular cytotoxicity or promote cell killing by use of ADCs. In addition, trastuzumab induces HER2 receptor down modulation, inhibits critical signaling pathways (i.e. ras-Raf-MAPK and PI3K/Akt), and blocks cell cycle progression by inducing the formation of p27/Cdk2 complexes, inhibits HER2 cleavage, preceding antibody-induced receptor down modulation, which may also contribute to its antitumor activity in some cancers. A limitation of trastuzumab is that its activity is largely restricted to breast cancers with the highest level of HER2 overexpression.

As described above, humanized antibodies against the HER2 receptor have been developed for the treatment of HER2-positive breast cancer. However, not all breast tumors are HER2-positive, some of them are HER2 negative and in some cases during treatment, HER2-positive cancers can transform into HER2 negative cancers, and then treatment is not effective. Also, many other tumors are HER2 negative. The constructs/conjugates described herein decorate all cancer cells (regardless of tissue of origin) with HER2 epitopes to enhance antibody therapy. Useful epitopes include a small peptide mimic of the receptor binding site or a protein-pHLIP® peptide fusion construct, where the protein resembles the entire extracellular domain of a receptor or part of it.

Non-limiting examples of HER2 mimicking peptides, which show high affinity binding to anti-HER-2 monoclonal antibody trastuzumab (Herceptin) include the following peptides:

(SEQ ID NO: 1) QVSHWVSGLAEGSFG (SEQ ID NO: 2) LSHTSGRVEGSVSLL (SEQ ID NO: 3) QMWAPQWGPD

The constructs are useful to decorate all cancer cells with HER2 epitopes to enhance antibody therapy. A useful epitope comprises a small peptide mimic of the receptor binding site or a protein-pHLIP® fusion construct, where the protein resembles the entire extracellular domain of a receptor or part of it. An additional strategy includes use a pHLIP® peptide to position epitopes for therapy using ADCs, some of which have been approved for clinical uses including trastuzumab emtansine, an anti-HER2 antibody conjugated with cytotoxic maytansinois payload (DM1 or mertansine), which is a potent tubulin inhibitor. By targeting the epitopes already in use, or by developing ADCs for new epitopes, the effective use of ADCs is significantly expanded. Other monoclonal antibodies developed for cancer treatment

In addition to anti-HER2 antibodies the non-limiting examples of monoclonal antibodies directed against different receptors currently in clinical use for cancer treatment include daratumumab (binds to CD38—cluster of differentiation 38); dinutuximab (binds to glycolipid GD2—disialoganglioside); bevacizumab (binds to VEGF-A—vascular endothelial growth factor A); cetuximab, necitumumab and panitumumab (bind to EGFR—epidermal growth factor); elotuzumab (binds to CD 319—cluster of differentiation 319), necitumumab (binds EGFR). ramucirumab (binds to VEGFR2). Epitope-pHLIP® constructs could be developed to use with all of these antibodies and their drug conjugates.

Other Examples of Peptide Epitopes

Non-limiting examples of peptide epitopes for conjugation to pHLIP® peptides for which monoclonal antibodies are already developed include:

MASMTGGQQMG (SEQ ID NO: 4): a T7 peptide derived from the T7 major capsid protein;

EQKLISEEDL (SEQ ID NO: 5): a Myc peptide derived from c-Myc;

YPYDVPDYA (SEQ ID NO: 6): a hemagglutinin (HA) peptide derived from hemagglutinin;

YTDIEMNRLGK (SEQ ID NO: 7): a vesiculovirus (VSV-G) peptide derived from the vesicular stomatitis viral glycoprotein;

KETAAAKFERQHMDS (SEQ ID NO: 8): an S peptide derived from pancreatic ribonuclease A;

GKPIPNPLLGLDST (SEQ ID NO: 9): a V5 peptide derived from the P and V proteins of the paramyxovirus of simian virus 5;

PDRVRAVSHWSS (SEQ ID NO: 15): a peptide derived from the protein beta-catenin and optimized for higher affinity binding to the Spot-Tag Nanobody;

DYKDDDDK (SEQ ID NO: 10): a FLAG synthetic peptide;

GAPVPYPDPLEPR (SEQ ID NO: ______) an E synthetic peptide;

HHHHHH (SEQ ID NO: 12): a Histidine synthetic peptide;

TKENPRSNQEESYDDNES (SEQ ID NO: 13): an NE synthetic peptide;

WSHPQFEK (SEQ ID NO: 14): a synthetic peptide recognized by streptavidin;

YTDIEMNRLGK (SEQ ID NO: 7): a vesicular stomatitis virus (VSV) synthetic peptide.

Protein Epitope pHLIP® Peptide Compositions

In addition to peptide epitopes, larger epitope-containing cytokine proteins may be used for the production of the compositions described. Cytokines are small proteins from 5 to 20 kDa, which perform immuno-modulating role. Among cytokine proteins are IL-17, TNF, CXCL and CCL chemokines.

For example, CXCL9, CXCL10 or CXCL11 chemokine is expressed as N-terminal part of pHLIP® to induce homing and activation of T-cells and NK-cells when pHLIP® inserts into cellular membrane and tethers CXCL9 or CXCL10 or CXCL11 proteins to surface of membrane.

The cytokine can be expressed together with a mucin-domain (a glycosylated protein) as a linker (spacer) between cytokine and pHLIP® peptide to allow the cytokine to be fully exposed to the extracellular space.

The nucleic acid sequence encoding CXCL10 chemokine and the amino acid sequence of the protein antigen is described below.

SEQ ID NO: 498 ccagtctcagcaccatgaatcaaactgccattctgatttgctgccttatct ttctgactctaagtggcattcaaggagtacctctctctagaactgtacgct gtacctgcatcagcattagtaatcaacctgttaatccaaggtctttagaaa aacttgaaattattcctgcaagccaattttgtccacgtgttgagatcattg ctacaatgaaaaagaagggtgagaagagatgtctgaatccagaatcgaagg ccatcaagaatttactgaaagcagttagcaaggaaaggtctaaaagatctc ct

The amino acid sequence of CXCL 10 is provided below.

(SEQ ID NO: 514) mnqtailicc lifltlsgiq gvplsrtvrc tcisisnqpv nprsleklei ipasqfcprv eiiatmkkkg ekrclnpesk aiknllkavs kerskrsp

His or myc tags are used for purification purposes and not needed for use as an antigen (e.g., for conjugation to a pHLIP® peptide).

Small Molecule Antigens or Epitopes

Small molecule antigens are those that are characterized by a molecular mass of less than 2000 daltons. For example, the molecular mass of the small molecule antigen is preferably less than 1000 daltons, more preferably less than 600 daltons, e.g., the compound is less than 500 daltons, 400 daltons, 300 daltons, 200 daltons, or 100 daltons. Some small molecule antigens are characterized by their binding to endogenous antibodies in the blood or serum of many normal humans (or humans characterized as having a pathological tumor).

Exemplary small molecule epitopes are described below.

Di-Nitrophenyl (DNP)

Antibodies to DNP (O-(2,4-dinitrophenyl)hydroxylamine, shown below) have been identified in the IgG fraction of normal human sera.

Thus, another small molecule antigen that binds endogenous antibodies is dinitrophenyl (DNP) and its derivatives. For example, N-(4-dimethylamino-3,5-dinitrophenyl)maleimide is shown below:

Or DNP-PEG4-NHS (1-(2,4-Dinitrophenylamino)-3,6,9,12-tetraoxapentadecanoic acid succinimidyl ester) is shown below:

DNP is a low molecular weight antigen known for its ability to bind antibodies in normal human serum. Binding of the antibodies to DNP delivered to the surface of tumor or otherwise diseased acidic cells leads to cytotoxicity of the antigen-labeled target cells. The DNP recruits endogenous antibodies, e.g., antibodies that exist in a subject prior to administration of the pHLIP® peptide constructs described herein.

Linker

In the schematic structure, Epitope-Linker-Peptide:

Linker could be relatively small, e.g., only a few atoms, to a rather large polar (or moderately hydrophobic) polymer or an N-terminal lengthening of the pHLIP® peptide by the addition of amino acids, e.g., glycine residues (poly-Gly). In some examples, a linker can be part of membrane non-inserting pHLIP® peptide sequence, such as those with a poly-Gly motif. In some examples, a linker could be PEG polymer. The purpose of a polymer or pHLIP® extension is to position epitopes at the surfaces of cells to enhance the access of antibodies or proteins for binding to the epitope. Non-limiting example of linker is a PEG polymer in size from 200 Da up to 20 kDa.

In some examples the following linkers and their derivatives could be used: N-α-maleimidoacet-oxysuccinimide ester (AMAS); N-γ-maleimidobutyryl-oxysuccinimide ester (GMBS); N-β-maleimidopropyl-oxysuccinimide ester (BMPS); N-ε-malemidocaproyl-oxysuccinimide ester (EMCS); m-maleimidobenzoyl-n-hydroxysuccinimide ester (MBS); succinimidyl 3-(bromoacetamido)propionate (SBAP); succinimidyl (4-iodoacetyl)aminobenzoate (SIAB); N-ε-maleimidocaproic acid (EMCA); succinimidyl 4-(n-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate) (LC-SMCC); succinimidyl iodoacetate (SIA); succinimidyl (4-iodoacetyl)aminobenzoate (SIAB); succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB); succinimidyl 6-((beta-maleimidopropionamido)hexanoate) (SMPH); 3-propargyloxypropanoic acid, succinimidyl ester (alkyne, succinimidyl ester); 1,4-bismaleimidobutane (BMB); bismaleimidohexane (BMH); bismaleimidoethane (BMOE); tris(2-maleimidoethyl)amine (TMEA); N-β-maleimidopropionic acid hydrazide; (BMPH); N-ε-maleimidocaproic acid hydrazide (EMCH); N-κ-maleimidoundecanoic acid hydrazide (KMUH); 4-(4-n-maleimidophenyl)butyric acid hydrazide (MBPH); or p-maleimidophenyl isocyanate (PMPI).

In some examples the flexible linker or mucin domain is positioned between epitope and pHLIP® peptide.

The mucin-domain of CX3CL1 and the nucleic acid sequence encoding mucin-domain of CX3CL1 is described below:

SEQ ID NO: 500 aatggcggcaccttcgagaagcagatcggcgaggtgaagcccaggaccacc cctgccgccgggggaatggacgagtctgtggtcctggagcccgaagccaca ggcgaaagcagtagcctggagccgactccttcttcccaggaagcacagagg gccctggggacctccccagagctgccgacgggtgtgactggttcctcaggg accaggctccccccgacgccaaaggctcaggatggagggcctgtgggcacg gagcttttccgagtgcctcccgtctccactgccgccacgtggcagagttct gctccccaccaacctgggcccagcctctgggctgaggcaaagacctctgag gccccgtccacccaggacccctccacccaggcctccactgcgtcctcccca gccccagaggagaatgctccgtctgaaggccagcgtgtgtggggtcagggg cagagccccaggccagagaactctctggagcgggaggagatgggtcccgtg ccagcgcacacggatgccttccaggactgggggcctggcagcatggcccac gtctctgtggtccctgtctcctcagaagggacccccagcagggagccagtg gcttcaggcagctggacccctaaggctgaggaacccatccatgccaccatg gacccccagaggctgggcgtccttatcactcctgtccctgacgcccaggct gccacccggaggcag

The sequence of mucin-domain of the human CX3CL1 protein (UniProt P78423 or NP_002987.1) is shown below (these are residues 111-141 from the human CX3CL1 protein):

SEQ ID NO: 526 gtfekqigev kprttpaagg mdesvvlepe atgessslep tpssqeaqra lgtspelptg vtgssgtrlp ptpkaqdggp vgtelfrvpp vstaatwqss aphqpgpslw aeaktseaps tqdpstqast asspapeena psegqrvwgq gqsprpensl ereemgpvpa htdafqdwgp gsmahvsvvp vssegtpsre pvasgswtpk aeepihatmd pqrlgvlitp vpdaqaatrr q

The full length CXCL1 amino acid dsequence is depicted below (NP_002987.1), and incorporated herein by reference.

SEQ ID NO: 527   1 mapislswll rlatfchltv llagqhhgvt kcnitcskmt skipvallih yqqnqascgk  61 raiiletrqh rlfcadpkeq wvkdamqhld rqaaaltrng gtfekqigev kprttpaagg 121 mdesvvlepe atgessslep tpssqeaqra lgtspelptg vtgssgtrlp ptpkaqdggp 181 vgtelfrvpp vstaatwqss aphqpgpslw aeaktseaps tqdpstqast asspapeena 241 psegqrvwgq gqsprpensl ereemgpvpa htdafqdwgp gsmahvsvvp vssegtpsre 301 pvasgswtpk aeepihatmd pqrlgvlitp vpdaqaatrr qavgllaflg llfclgvamf 361 tyqslqgcpr kmagemaegl ryiprscgsn syvlvpv

Exemplary landmark residues, domains, and fragments of CXCL1 include, but are not limited to residues 1-24 (signal peptide), residues 25-397 (mature peptide), or residues 111-141 (as described above). A fragment (e.g., a peptide or an epitope) of a CXCL1 protein is less than the length of the full length protein, e.g., a fragment is at least 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 200 or more residues in length, but less than e.g., 397 residues in the case of CXCL1 above.

pHLIP® Peptides

In the schematic structure, Epitope-Linker-Peptide:

Peptide is a pHLIP® peptide (non-limiting example is pHLIP® comprising the Var3 sequence AXDDQNPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______) or AXDQDNPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______), where X is a functional group for conjugation purposes, selected from a lysine (Lys), a cysteine (Cys), or Azido-containing amino acid or others. The membrane non-inserting N-terminal flanking sequence of pHLIP® peptide can be extend. For example, the pHLIP® peptide shares the sequence:

(SEQ ID NO: 112) WRAYLDLLFPTDTLLLDLLW.

Non-limiting examples of the extension can be poly-Gly motif or AX(Z)_(n)XPWRAYLDLLFPTDTLLLDLLWA, where “Z” indicates any amino acid residue, and n is any integer between and including 1-10 (e.g., 1≤n≤10). Additionally, (Z)_(n) could be QDNDQN (SEQ ID NO: ______) or NENENN (SEQ ID NO: 528) or NDNDNN (SEQ ID NO: 529) or NDNDNDN (SEQ ID NO:530), any combination of polar residues. D, E, N or Q.

An example of a wild type (WT) pHLIP® peptide is AXEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT (SEQ ID NO: 20) where X is a functional group for conjugation purposes, selected from a lysine (Lys), a cysteine (Cys), an Azido-containing amino acid, or others, and in which AEQNPIY (SEQ ID NO: ______) represents a flanking sequence, WARYADWLFTTPLLLLDLALLV (SEQ ID NO: 21) represents a membrane-inserting sequence, and DADEGT represents a flanking sequence.

The constructs may include a pHLIP® peptide with a N-terminal extension. For example, the N terminus of any of these peptide sequences can be extended by the addition of amino acids to space the epitope away from the cell surface, e.g. by including a (glycine) extension.

Other exemplary pHLIP® peptides are shown in the Tables below.

TABLE 1 Exemplary pHLIP ® peptides Name Sequence SEQ ID No. Var3-1a ACDQDNPWRAYLDLLFPTDTLLLDLLWA SEQ. ID NO.    Var3-1b AKDQDNPWRAYLDLLFPTDTLLLDLLWA SEQ. ID NO.    Var3-2a ACQDNDQNCPWRAYLDLLFPTDTLLLDLLWA SEQ. ID NO.    Var3-2b AKQDNDQNKPWRAYLDLLFPTDTLLLDLLWA SEQ. ID NO.    WT-1 GGEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT SEQ. ID NO. 22 WT-2 AEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT SEQ. ID NO. 23 Var3-WT-Cys ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG SEQ. I NO. 24 Cys-Var3-WT ACDDQNPWRAYLDLLFPTDTLLLDLLWDADEG SEQ. I NO. 25 Lys-Var3-WT AKDDQNPWRAYLDLLEPTDTELLDLLWDADEG SEQ. I NO. 26 WT-Cys1 AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG SEQ. ID NO. 27 WT-Cys2 Ac-AEQNPIYWARYADWLFTTPLLLLDLALLVDADEGCT SEQ ID NO: 28 WT-Cys3 GGEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG SEQ. ID NO. 29 Cys-WT1 Ac-ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTG SEQ. ID NO. 30 Var0-NT ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT SEQ. ID NO. 31 Lys-WT1 AKEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT SEQ. ID NO. 32 Lys-WT2 Ac-AKEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTG SEQ ID NO: 33 WT-KC AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTKCG SEQ. ID NO. 34 K-WT-C AKEQNPIYWARYADWLFTTPLLLLDLALLVDADECT SEQ. ID NO. 35 N-pHLIP ® ACEQNPIYWARYANWLFTTPLLLLNLALLVDADEGTG SEQ. ID NO. 36 N-pHLIP ®-b ACEQNPIYWARYANWLFTTPLLLLNLALLVDADEGT SEQ ID NO: 37 K-pHLIP ® ACEQNPIYWARYAKWLFTTPLLLLKLALLVDADEGTG SEQ. ID NO. 38 NNQ GGEQNPIYWARYADWLFTTPLLLLDLALLVNANQGT SEQ. ID NO. 39 D25A AAEQNPIYWARYADWLFTTPLLLLALALLVDADEGT SEQ. ID NO. 40 D25A-KC Ac-AAEQNPIYWARYADWLFTTPLLLLELALLVDADEGTKCG SEQ ID NO: 41 D14A AAEQNPIYWARYAAWLFTTPLLLLDLALLVDADEGT SEQ. ID NO. 42 P20A AAEQNPIYWARYADWLFTTALLLLDLALLVDADEGT SEQ. ID NO. 43 D25E AAEQNPIYWARYADWLFTTPLLLLELALLVDADEGT SEQ. ID NO. 44 D14E AAEQNPIYWARYAEWLFTTPLLLLDLALLVDADEGT SEQ. ID NO. 45 3D AAEQNPIIYWARYADWLFTDLPLLLLDLLALLVDADEGT SEQ. ID NO. 46 R11Q GEQNPIYWAQYADWLFTTPLLLLDLALLVDADEGTCG SEQ. ID NO. 47 D25Up GGEQNPIYWARYADWLFTTPLLLDLLALLVDADEGTCG SEQ. ID NO. 48 D25Down GGEQNPIYWARYADWLFTTPLLLLLDALLVDADEGTCG SEQ. ID NO. 49 D14Up GGEQNPIYWARYDAWLFTTPLLLLDLALLVDADEGTCG SEQ. ID NO. 50 D14Down GGEQNPIYWARYAWDLFTTPLLLLDLALLVDADEGTCG SEQ. ID NO. 51 P20G AAEQNPIYWARYADWLFTTGLLLLDLALLVDADEGT SEQ. ID NO. 52 H1-Cys DDDEDNPIYWARYADWLFTTPLLLLHGALLVDADECT SEQ. ID NO. 53 H1 DDDEDNPIYWARYADWLFTTPLLLLHGALLVDADET SEQ ID NO: 54 H2-Cys DDDEDNPIYWARYAHWLFTTPLLLLHGALLVDADEGCT SEQ. ID NO. 55 Cys-H2 CDDDEDNPIYWARYAHWLFTTPLLLLHGALLVDADET SEQ ID NO: 56 H2 DDDEDNPIYWARYAHWLFTTPLLLLHGALLVDADEGT SEQ ID NO: 57 H2N-Cys DDDEDNPIYWARYAHWLFTTPLLLLHGALLVNADECT SEQ. ID NO. 58 H2N DDDEDNPIYWARYAHWLFTTPLLLLHGALLVNADEGT SEQ ID NO: 59 H2N2-Cys DDDEDNPIYWARYAHWLFTTPLLLLHGALLVNANECT SEQ. ID NO. 60 H2N2 DDDEDNPIYWARYAHWLFTTPLLLLHGALLVNANEGT SEQ ID NO: 61 1a-Trp AEQNPIYWARYADFLFTTPLLLLDLALLVDADET SEQ. ID NO. 62 1b-Trp AEQNPIYFARYADWLFTTPLLLLDLALLVDADEGT SEQ. ID NO. 63 1c-Trp AEQNPIYFARYADFLFTTPLLLLDLALLWDADET SEQ. ID NO. 64 Fast-1 or Var1 AKEDQNPYWARYADWLFTTPLLLLDLALLVDG SEQ. ID NO. 65 Var1-2D1D ACEDQNPYWARYADWLFTTPLLLLDLALLVDG SEQ. ID NO. 66 Fast1-Cys or AEDQNPYWARYADWLFTTPLLLLDLALLVDCG SEQ. ID NO. 67 Var1-2D1D-Cys Fast1-E-Cys or AEDQNPYWARYADWLFTTPLLLLELALLVECG SEQ. ID NO. 68 Var1E Fast1-E-Lys AKEDQNDPYWARYADWLFTTPLLLLDLALLVG SEQ ID NO: 69 Fast2 or Var2 AKEDQNPYWRAYADLFTPLTLLDLLALWDG SEQ. ID NO. 70 Fast2-E-Cys or AEDQNPYWARYADWLFTTPLLLLELALLVCG SEQ ID NO: 71 Var2E Var2-2D1D ACEDQNPYWRAYADLFTPLTLLDLLALWDG SEQ. ID NO. 72 Var3-3D ACDDQNPWRAYLDLLFPTDTLLLDLLW SEQ. ID NO. 73 Var3-3D-cys AKDDQNPWRAYLDLLFPTDTLLLDLLWC SEQ ID NO: 74 Var4-3E ACEEQNPWRAYLELLFPTETLLLELLW SEQ ID NO: 75 Var5-3Da ACDDQNPWARYLDWLFPTDTLLLDL SEQ ID NO: 76 Var6-3Db CDNNNPWRAYLDLLFPTDTLLLDW SEQ ID NO: 77 Var8-3Eb CEEQQPWAQYLELLFPTETLLLEW SEQ ID NO: 78 Var9-3Ec CEEQQPWRAYLELLFPTETLLLEW SEQ ID NO: 79 Var15-2N CDDDDDNPNYWARYANWLFTTPLLLLNGALLVEAEET SEQ ID NO: 80 Var16-2P CDDDDDNPNYWARYAPWLFTTPLLLLPGALLVEAEE SEQ ID NO: 81

TABLE 2 Exemplary pHLIP ® peptides Name Sequence SEQ ID No. Var14- Ac-TEDADVLLALDLLLLPTTFLW SEQ. ID NO. 82 Rev DAYRAWYPNQECA-Am Sh AEQNPIYWARYADWLFTTPL SEQ. ID NO. 83 Sh-Cys AEQNPIYWARYADWLFTTPCL SEQ. ID NO. 84 Cys-Sh ACEQNPIYWARYADWLFTTPL SEQ. ID NO. 85 Sh-1Trp AEQNPIYFARYADWLFTTPL SEQ. ID NO. 86 Sh-W2 AEQNPIYFARYADLLFPTTLAW SEQ ID NO: 87 Sh-W1 AEQNPIYWARYADLLFPTTLAF SEQ ID NO: 88 Sh-2W AEQNPIYWARYADLLFPTTLAW SEQ ID NO: 89 Sh-1D KEDQNPWARYADLLFPTTLAW SEQ. ID NO. 90 Sh-1Db KEDQNPWARYADLLFPTTLW SEQ ID NO: 91 Var12-1D ACEDQNPWARYADLLFPTTLAW SEQ. ID NO. 92 Var10-2D ACEDQNPWARYADWLFPTTLLLLD SEQ. ID NO. 93 Var13-1E ACEEQNPWARYAELLFPTTLAW SEQ. ID NO. 94 Var11-2E ACEEQNPWARYAEWLFPTTLLLLE SEQ. ID NO. 95 Var7-3E ACEEQNPWARYLEWLFPTETLLLEL SEQ. ID NO. 96 Var7-3Eb ACEEQNPQAEYAEWLFPTTLLLLE SEQ ID NO: 97 “Ac” means Acetylated N-terminus “Am” means Amidated C-terminus

TABLE 3 Coded and exemplary non-coded amino acids including L-isomers, D- isomers, alpha-isomers, beta-isomers, glycol-, and methyl- modifications. No. Abbrev Name 1 Ala Alanine 2 Arg Arginine 3 Asn Asparagine 4 Asp Aspartic acid 5 Cys Cysteine 6 Gln Glutamine 7 Glu Glutamic acid 8 Gly Glycine 9 His Histidine 10 Ile Isoleucine 11 Leu Leucine 12 Lys Lysine 13 Met Methionine 14 Phe Phenylalanine 15 Pro Proline 16 Ser Serine 17 Thr Threonine 18 Trp Tryptophan 19 Tyr Tyrosine 20 Val Valine 21 Sec Selenocysteine 22 Sem Selenomethionine 23 Pyl Pyrrolysine 24 Aad Alpha-aminoadipic acid 25 Acpa Amino-caprylic acid 26 Aecys Aminoethyl cysteine 27 Afa Aminophenyl acetate 28 Gaba Gamma-aminobutyric acid 29 Aiba Aminoisobutyric acid 30 Aile Alloisoleucine 31 AIg Allylglycine 32 Aba Amino-butyric acid 33 Aphe Amino-phenylalanine 34 Brphe Bromo-phenylalanine 35 Cha Cyclo-hexylalanine 36 Cit Citrulline 37 Clala Chloroalanine 38 Cie Cycloleucine 39 Clphe Fenclonine (or chlorophenylalanine) 40 Cya Cysteic acid 41 Dab Diaminobutyric acid 42 Dap Diaminopropionic acid 43 Dap Diaminopimelic acid 44 Dhp Dehydro-proline 45 Dhphe DOPA (or 3,4-dihydroxyphenylalanine) 46 Fphe Fluorophenylalanine 47 Gaa Glucosaminic acid 48 Gla Gamma-carboxyglutamic acid 49 Hag Homoarginine 50 Hlys Hydroxylysine 51 Hnvl Hydroxynorvaline 52 Hog Homoglutamine 53 Hoph Homophenylalanine 54 Has Homoserine 55 Hse Homocysteine 56 Hpr Hydroxyproline 57 Iphe Iodo-phenylalanine 58 Ise Isoserine 59 Mle Methyl-leucine 60 Msmet Methionine-methylsulfonium chloride 61 Nala Naphthyl-alanine 62 Nle Norleucine (or 2-aminohexanoic acid) 63 Nmala N-methyl-alanine 64 Nva Norvaline (or 2-aminopentanoic acid) 65 Obser O-benzyl-serine 66 Obtyr O-benzyl-tyrosine 67 Oetyr O-ethyl-tyrosine 68 Omser O-methyl-serine 69 Omthr O-methy-threonine 70 Omtyr O-methyl-tyrosine 71 Orn Ornithine 72 Pen Penicillamine 73 Pga Pyroglutamic acid 74 Pip Pipecolic acid 75 Sar Sarcosine 76 Tfa Trifluoro-alanine 77 Thphe Hydroxy-Dopa 78 Vig Vinylglycine 79 Aaspa Amino-aminoethylsulfanylpropanoic acid 80 Ahdna Amino-hydroxy-dioxanonanolic acid 81 Ahoha Amino-hydroxy-oxahexanoic acid 82 Ahsopa Amino-hydroxyethylsulfanylpropanoic acid 83 Tyr(Me) Methoxyphenyl-methylpropanyl oxycarbonylamino propanoic acid 84 MTrp Methyl-tryptophan 85 pTyr Phosphorylated Tyr 86 pSer Phosphorylated Ser 87 pThr Phosphorylated Thr 88 BLys BiotinLys 89 Hyp Hydroproline 90 Phg Phenylglycine 91 Cha Cyclohexyl-alanine 92 Chg Cyclohexylglycine 93 Nal Naphthylalanine 94 Pal Pyridyl-alanine 95 Pra Propargylglycine 96 Gly(allyl) Pentenoic acid 97 Pen Penicillamine 98 MetO Methionine sulfoxide 99 Pca Pyroglutamic acid 100 Ac-Lys Acetylation of Lys

TABLE 4 Non-limiting examples of protonatable residues and their substitutions including L-isomers, D- isomers, alpha-isomers, and beta-isomers. Original Residue Exemplary amino acids substitution Asp (D) Glu (E); Gla (Gla); Aad (Aad) Glu (E) Asp (D); Gla (Gla); Aad (Aad)

TABLE 5 Examples of coded amino acid substitutions Original Residue Substitution Ala (A) Gly; Ile; Leu; Met; Phe; Pro; Trp; Tyr; Val Arg (R) Lys Asn (N) Gln; His Asp (D) Glu Cys (C) Ser; Met Gln (Q) Asn; His Glu (E) Asp Gly (G) Ala; Ile; Leu; Met; Phe; Pro; Trp; Tyr; Val His (H) Asn; Gln Ile (I) Ala; Gly; Leu; Met; Phe; Pro; Trp; Tyr; Val Leu (L) Ala; Gly; Ile; Met; Phe; Pro; Trp; Tyr; Val Lys (K) Arg Met (M) Ala; Gly; Leu; Ile; Phe; Pro; Trp; Tyr; Val Phe (F) Ala; Gly; Leu; Ile; Met; Pro; Trp; Tyr; Val Pro (P) Ala; Gly; Leu; Ile; Met; Phe; Trp; Tyr; Val Ser (S) Thr Thr (T) Ser Trp (W) Ala; Gly; Leu; Ile; Met; Pro; Phe; Tyr; Val Tyr (Y) Ala; Gly; Leu; Ile; Met; Pro; Phe; Trp; Val Val (V) Ala; Gly; Leu; Ile; Met; Pro; Phe; Trp; Tyr

TABLE 6 Non-limiting examples of membrane-inserting sequences belonging to different groups of pHLIP ® peptides. Each protonatable residue (shown in bold) could be replaced by its  substitution from Table 4. Each non-polar  residue could be replaced by its coded amino  acid substitution from Table 5, and/or non- coded amino acid substitutions from Table 3. Groups Sequences WT-BRC WARYADWLFTTPLLLLDLALL (SEQ ID NO: 98) YARYADWLFTTPLLLLDLALL (SEQ ID NO: 99) WARYSDWLFTTPLLLYDLGLL (SEQ ID NO: 100) WARYTDWFTTPLLLYDLALLA (SEQ ID NO: 101) WARYTDWLFTTPLLLYDLGLL (SEQ ID NO: 102) WARYADWLFTTPLLLLDLSLL (SEQ ID NO: 103) WT-BRC LLALDLLLLPTTFLWDAYRAW (SEQ ID NO: 104) Reverse LLALDLLLLPTTFLWDAYRAY (SEQ ID NO: 105) LLGLDYLLLPTTFLWDSYRAW (SEQ ID NO: 106) ALLALDYLLLPTTFWDTYRAW (SEQ ID NO: 107) LLGLDYLLLPTTFLWDTYRAW (SEQ ID NO: 108) LLSLDLLLLPTTFLWDAYRAW (SEQ ID NO: 109) ATRAM GLAGLLGLEGLLGLPLGLLEGLWLGL (SEQ ID NO: 110) ATRAM LGLWLGELLGLPLGLLGELGLLGALG (SEQ ID Reverse NO: 111) Var3 WRAYLDLLFPTDTLLLDLLW (SEQ ID NO: 112) Var3 WLLDLLLTDTPFLLDLYARW (SEQ ID NO: 113) Reverse Var7 WARYLEWLFPTETLLLEL (SEQ ID NO: 114) WAQYLELLFPTETLLLEW (SEQ ID NO: 115) Var7 LELLLTETPFLWELYRAW (SEQ ID NO: 116) Reverse WELLLTETPFLLELYQAW (SEQ ID NO: 117) Single WLFTTPLLLLNGALLVE (SEQ ID NO: 118) D/E WLFTTPLLLLPGALLVE (SEQ ID NO: 119) WARYADLLFPTTLAW (SEQ ID NO: 120) Single EVLLAGNLLLLPTTFLW (SEQ ID NO: 121) D/E EVLLAGPLLLLPTTFLW (SEQ ID NO: 122) Reverse WALTTPFLLDAYRAW (SEQ ID NO: 123) pHLIP ®- NLEGFFATLGGEIALWSLVVLAIE (SEQ ID NO: 124) Rho EGFFATLGGEIALWSDVVLAIE (SEQ ID NO: 125) EGFFATLGGEIPLWSDVVLAIE (SEQ ID NO: 126) pHLIP ®- EIALVVLSWLAIEGGLTAFFGELN (SEQ ID NO: 127) Rho EIALVVDSWLAIEGGLTAFFGE (SEQ ID NO: 128) Reverse EIALVVDSWLPIEGGLTAFFGE (SEQ ID NO: 129) pHLIP ®- ILDLVFGLLFAVTSVDFLVQW (SEQ ID NO: 130) CA9 pHLIP ®- WQVLFDVSTVAFLLGFVLDLI (SEQ ID NO: 131) CA9 Reverse

TABLE 7 Non-limiting examples of pHLIP ® sequences. A cysteine, a lysine, an azido-modified amino acid, or an alkynyl modified amino acid can be incorporated at the N-terminal (first 6 residues) or C- terminal (last 6 residues) parts of the peptides for conjugation with a cargo, and a linker. SEQ ID NO Name Sequence SEQ ID NO: 132 WT-2D AEQNPIYWARYADWLFTTPLLLLDLALLVDADET SEQ ID NO: 133 WT-6E AEQNPIYWARYAEWLFTTPLLLLELALLVEAEET SEQ ID NO: 134 WT-3D ADDQNPWRAYLDLLFPDTTDLLLLDLLWDADET SEQ ID NO: 135 WT-9E AEEQNPWRAYLELLFPETTELLLLELLWEAEET SEQ ID NO: 136 WT-GlaD AEQNPIYWARYAGlaWLFTTPLLLLDLALLVDADET SEQ ID NO: 137 WT-DGla AEQNPIYWARYADWLFTTPLLLLGlaLALLVDADET SEQ ID NO: 138 WT-2G1a AEQNPIYWARYAGlaWLFTTPLLLLGlaLALLVDADET SEQ ID NO: 139 WT-AadD AEQNPIYWARYAAadWLFTTPLLLLDLALLVDADET SEQ ID NO: 140 WT-DAad AEQNPIYWARYADWLFTTPLLLLAadLALLVDADET SEQ ID NO: 141 WT-2Aad AEQNPIYWARYAAadWLFTTPLLLLAadLALLVDADET SEQ ID NO: 142 WT-GlaAad AEQNPIYWARYAGlaWLFTTPLLLLAadLALLVDADET SEQ ID NO: 143 WT-AadGla AEQNPIYWARYAAadWLFTTPLLLLGlaLALLVDADET SEQ ID NO: 144 WT-1 GGEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT SEQ ID NO: 145 WT-2 GGEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT SEQ ID NO: 146 WT-3 AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT SEQ ID NO: 147 WT-4 AEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT SEQ ID NO: 148 WT-2N AEQNPIYWARYANWLFTTPLLLLNLALLVDADEGT SEQ ID NO: 149 WT-2K AEQNPIYWARYAKWLFTTPLLLLKLALLVDADEGT SEQ ID NO: 150 WT-2DNANQ GGEQNPIYWARYADWLFTTPLLLLDLALLVNANQGT SEQ ID NO: 151 WT-D25A AAEQNPIYWARYADWLFTTPLLLLALALLVDADEGT SEQ ID NO: 152 WT-D14A AAEQNPIYWARYAAWLFTTPLLLLDLALLVDADEGT SEQ ID NO: 153 WT-P20A AAEQNPIYWARYADWLFTTALLLLDLALLVDADEGT SEQ ID NO: 154 WT-D25E AAEQNPIYWARYADWLFTTPLLLLELALLVDADEGT SEQ ID NO: 155 WT-D14E AAEQNPIYWARYAEWLFTTPLLLLDLALLVDADEGT SEQ ID NO: 156 WT-3D-2 AAEQNPIIYWARYADWLFTDLPLLLLDLLALLVDADEGT SEQ ID NO: 157 WT-R11Q GEQNPIYWAQYADWLFTTPLLLLDLALLVDADEG SEQ ID NO: 158 WT-D25Up GGEQNPIYWARYADWLFTTPLLLDLLALLVDADEG SEQ ID NO: 159 WT-D25Down GGEQNPIYWARYADWLFTTPLLLLLDALLVDADEG SEQ ID NO: 160 WT-D14Up GGEQNPIYWARYDAWLFTTPLLLLDLALLVDADEGT SEQ ID NO: 161 WT-D14Down GGEQNPIYWARYAWDLFTTPLLLLDLALLVDADEG SEQ ID NO: 162 WT-P20G AAEQNPIYWARYADWLFTTGLLLLDLALLVDADEGT SEQ ID NO: 163 WT-DH DDDEDNPIYWARYADWLFTTPLLLLHGALLVDAD SEQ ID NO: 164 WT-2H DDDEDNPIYWARYAHWLFTTPLLLLHGALLVDADE SEQ ID NO: 165 WT-L16H CEQNPIYWARYADWHFTTPLLLLDLALLVDADE SEQ ID NO: 166 WT-1Wa AEQNPIYWARYADFLFTTPLLLLDLALLVDADET SEQ ID NO: 167 WT-1Wb AEQNPIYFARYADWLFTTPLLLLDLALLVDADE SEQ ID NO: 168 WT-1Wc AEQNPIYFARYADFLFTTPLLLLDLALLWDADET SEQ ID NO: 169 WT-W6 ADNNPWIYARYADLTTFPLLLLDLALLVDFDD SEQ ID NO: 170 WT-W17 ADNNPFIYARYADLTTWPLLLLDLALLVDFDD SEQ ID NO: 171 WT-W30 ADNNPFIYARYADLTTFPLLLLDLALLVDWDD SEQ ID NO: 172 WT-W17-P7 ADNNPFPYARYADLTTWILLLLDLALLVDFDD SEQ ID NO: 173 WT-W39-R11 ADNNPFIYAYRADLTTFPLLLLDLALLVDWDD SEQ ID NO: 174 WT-W30-R15 ADNNPFIYATYADLRTFPLLLLDLALLVDWDD SEQ ID NO: 175 WT-Rev Ac-TEDADVLLALDLLLLPTTFLWDAYRAWYPNQEA-Am SEQ ID NO: 176 Var1-3D AEDQNPYWARYADWLFTTPLLLLDLALLVD SEQ ID NO: 177 Var1-1D2E AEDQNPYWARYADWLFTTPLLLLELALLVE SEQ ID NO: 178 Var2-3D AEDQNPYWRAYADLFTPLTLLDLLALWD SEQ ID NO: 179 Var3-3D ADDQNPWRAYLDLLFPTDTLLLDLLW SEQ ID NO: 180 Var3-WT ADDQNPWRAYLDLLFPTDTLLLDLLWDADE SEQ ID NO: 181 Var3-Gla2D ADDQNPWRAYLGlaLLFPTDTLLLDLLW SEQ ID NO: 182 Var3-DGlaD ADDQNPWRAYLDLLFPTGlaTLLLDLLW SEQ ID NO: 183 Var3-2DGla ADDQNPWRAYLDLLFPTDTLLLGlaLLW SEQ ID NO: 184 Var3-2GlaD ADDQNPWRAYLGlaLLFPTGlaTLLLDLLW SEQ ID NO: 185 Var3-GlaDGla ADDQNPWRAYLGlaLLFPTDTLLLGlaLLW SEQ ID NO: 186 Var3-D2Gla ADDQNPWRAYLDLLFPTGlaTLLLGlaLLW SEQ ID NO: 187 Var3-3Gla ADDQNPWRAYLGlaLLFPTGlaTLLLGlaLLW SEQ ID NO: 188 Var3-Aad2D ADDQNPWRAYLAadLLFPTDTLLLDLLW SEQ ID NO: 189 Var3-DAadD ADDQNPWRAYLDLLFPTAadTLLLDLLW SEQ ID NO: 190 Var3-2DAad ADDQNPWRAYLDLLFPTDTLLLAadLLW SEQ ID NO: 191 Var3-2AadD ADDQNPWRAYLAadLLFPTAadTLLLDLLW SEQ ID NO: 191 Var3-AadDAad ADDQNPWRAYLAadLLFPTDTLLLAadLLW SEQ ID NO: 192 Var3-D2Aad ADDQNPWRAYLDLLFPTAadTLLLAadLLW SEQ ID NO: 193 Var3-3Aad ADDQNPWRAYLAadLLFPTAadTLLLAadLLW SEQ ID NO: 194 Var3-GlaAadD ADDQNPWRAYLGlaLLFPTAadTLLLDLLW SEQ ID NO: 195 Var3-GlaDAad ADDQNPWRAYLGlaLLFPTDTLLLAadLLW SEQ ID NO: 196 Var3-2GlaAad ADDQNPWRAYL

LLFPT

TLLL

LLW SEQ ID NO: 197 Var3-AadGlaD ADDQNPWRAYL

LLFPT

TLLLDLLW SEQ ID NO: 198 Var3-AadDGla ADDQNPWRAYL

LLFPTDTLLL

LLW SEQ ID NO: 199 Var3-GlaAadGla ADDQNPWRAYL

LLFPT

TLLL

LLW SEQ ID NO: 200 Var3-GLL GEEQNPWLGAYLDLLFPLELLGLLELGLW SEQ ID NO: 201 Var3-M ADDDDDDPWQAYLDLLFPTDTLLLDLLW SEQ ID NO: 202 Var4-3E AEEQNPWRAYLELLFPTETLLLELLW SEQ ID NO: 203 Var5-3Da ADDQNPWARYLDWLFPTDTLLLDL SEQ ID NO: 204 Var6-3Db DNNNPWRAYLDLLFPTDTLLLDW SEQ ID NO: 205 Var7-3E AEEQNPWARYLEWLFPTETLLLEL SEQ ID NO: 206 Var7-M DDDDDDPWQAYLDLFPTDTLALDLW SEQ ID NO: 207 Var8-3E EEQQPWAQYLELLFPTETLLLEW SEQ ID NO: 208 Var9-3E EEQQPWRAYLELLFPTETLLLEW SEQ ID NO: 209 Var10-2D AEDQNPWARYADWLFPTTLLLLD SEQ ID NO: 210 Var11-2E AEEQNPWARYAEWLFPTTLLLLE SEQ ID NO: 211 Var12-1D AEDQNPWARYADLLFPTTLAW SEQ ID NO: 212 Var13-1E AEEQNPWARYAELLFPTTLAW SEQ ID NO: 213 Var15-2N DDDDDNPNYWARYANWLFTTPLLLLNGALLVEAEET SEQ ID NO: 214 Var16-2P DDDDDNPNYWARYAPWLFTTPLLLLPGALLVEAEET SEQ ID NO: 215 Var17 AEQNPIYFARYADFLFTTPLLLLDLALLWDADET SEQ ID NO: 216 Var18 AEQNPIYWARYADFLFTTPLLLLDLALLVDADET SEQ ID NO: 217 Var19a AEQNPIYWARYADWLFTTPL SEQ ID NO: 218 Var20 AEQNPIYFARYADLLFPTTLAW SEQ ID NO: 219 Var21 AEQNPIYWARYADLLFPTTLAF SEQ ID NO: 220 Var22 AEQNPIYWARYADLLFPTTLAW SEQ ID NO: 221 Var23 AEQNPIYFARYADWLFTTPL SEQ ID NO: 222 Var24 EDQNPWARYADLLFPTTLAW SEQ ID NO: 223 ATRAM GLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN SEQ ID NO: 224 pHLIP ®-CA9 EQNPIYILDLVFGLLFAVTSVDFLVQWDDAGD SEQ ID NO: 225 pHLIP ®-Rho NLEGFFATLGGEIALWSLVVLAIE SEQ ID NO: 226 pHLIP ®-RhoM1 NNEGFFATLGGEIALWSDVVLAIE SEQ ID NO: 227 pHLIP ®-RhoM2 DNNEGFFATLGGEIPLWSDVVLAIE

Epitopes may also be delivered to the cell surface of target cells (tumor cells and other diseased tissues/cells) using cyclic pHLIP® peptides. A cyclic peptide is one that comprises a circle geometry or structure. For example, the entire structure of the peptide is circular or a portion of the structure is circular. For example, in the latter case the peptide comprises a cyclic portion and a linear (or tail) portion. In various embodiments, a pH triggered peptide comprises at least 4 amino acids, where (a) at least 2 of the at least 4 amino acids of the peptide are non-polar amino acids, (b) at least 1 of the at least 4 amino acids of the peptide is a protonatable amino acid, and (c) the peptide has a higher affinity to a membrane lipid bilayer at pH 5.0 compared to at pH 8.0. Such pHLIP® peptides are described in International Patent Application No. PCT/US2017/023458 (PCT publication no. WO2017/165452A1, hereby incorporated by reference.

Exemplary cyclic pHLIP® peptides are described and shown below. A lowercase “c” at the beginning of a sequence herein denotes a cyclic peptide (e.g., as in c[WE)₃WC]) (SEQ ID NO: 1), and a lowercase “l” denotes a linear peptide (e.g., as in l(CW(EW)₄)) (SEQ ID NO: 188). In the case of cyclic structures that comprise a tail, the cyclic portion of the compound is within brackets, and the tail portion follows (is to the right of) the brackets. For example, in the compound c[E₅K]W₅C, c[E₅K] is the cyclic peptide portion, and W₅C is the peptide tail portion. As another example, in c[E₅K]W₄C, the cyclic peptide portion is c[E₅K] and the peptide tail portion is W₄C.

With respect to cyclic peptides, the amino acids within brackets may be present in the order listed in brackets from left to right, or in any order. For example, a cyclic peptide c[X₂Y₂] may have the corresponding linear sequence: XXYY, XYXY, YXXY, XYYX, or YXYX. In some cases, multiple examples of corresponding linear sequences for an exemplary cyclic peptide are listed in Table 3.

Table 8 provides a summary of peptide sequences.

Peptide Sequence Linear Sequence SEQ ID NO 1 c[(WE)₃WC] WEWEWEWC 228 2 c[(WE)₄WC] WEWEWEWEWC 229 3 c[(WE)₅WC] WEWEWEWEWEWC 230 4 c[(LE)₄WC] LELELELEWC 231 5 c[E₄W₅C] EEEEWWWWWC 232 6 l(CW(EW)₄) CWEWEWEWEW 233 7 c[R₄W₅C] RRRRWWWWWC 234

In column 2 (“Sequence”, the lower case “c” indicates “circular peptide, and the lower case “l” indicated linear peptide.

Table 9 provides additional non-limiting examples of peptide sequences.

Cy- clic Pep- Circular Linear tide Sequence Sequence SEQ ID NO   1 c[E₃W₅C] EEEWWWWWC 235   2 c[E₃W₅C] EWEWWWWEC 236   3 c[E₃W₅C] EWWEWWWEC 237   4 c[E₃W₅C] EWWWEWWEC 238   5 c[E₃W₅C] EWWWWEWEC 239   6 c[E₃W₅C] EWWWWWEEC 240   7 c[E₃W₅C] EWEEWWWWC 241   8 c[E₃W₅C] EWWEEWWWC 242   9 c[E₃W₅C] EWWWEEWWC 243  10 c[E₃W₅C] EWWWWEEWC 244  11 c[E₃W₅C] WEEEWWWWC 245  12 c[E₃W₅C] WWEEEWWWC 246  13 c[E₃W₅C] WWWEEEWWC 247  14 c[E₃W₅C] WWWWEEEWC 248  15 c[E₃W₅C] WEWEEWWWC 249  16 c[E₃W₅C] WEWWEEWWC 250  17 c[E₃W₅C] WEWWWEEWC 251  18 c[E₃W₅C] WEWWWWEEC 252  19 c[E₃W₅] EEEWWWWW 253  20 c[E₃W₅] EWEWWWWE 254  21 c[E₃W₅] EWWEWWWE 255  22 c[E₃W₅] EWWWEWWE 256  23 c[E₃W₅] EWWWWEWE 257  24 c[E₃W₅] EWWWWWEE 258  25 c[E₃W₅] EWEEWWWW 259  26 c[E₃W₅] EWWEEWWW 260  27 c[E₃W₅] EWWWEEWW 261  28 c[E₃W₅] EWWWWEEW 262  29 c[E₃W₅] WEEEWWWW 263  30 c[E₃W₅] WWEEEWWW 264  31 c[E₃W₅] WWWEEEWW 265  32 c[E₃W₅] WWWWEEEW 266  33 c[E₃W₅] WEWEEWWW 267  34 c[E₃W₅] WEWWEEWW 268  35 c[E₃W₅] WEWWWEEW 269  36 c[E₃W₅] WEWWWWEE 270  37 c[D₃W₅C] DDDWWWWWC 271  38 c[D₃W₅C] DWDWWWWDC 272  39 c[D₃W₅C] DWWDWWWDC 273  40 c[D₃W₅C] DWWWDWWDC 274  41 c[D₃W₅C] DWWWWDWDC 275  42 c[D₃W₅C] DWWWWWDDC 276  43 c[D₃W₅C] DWDDWWWWC 277  44 c[D₃W₅C] DWWDDWWWC 278  45 c[D₃W₅C] DWWWDDWWC 279  46 c[D₃W₅C] DWWWWDDWC 280  47 c[D₃W₅C] WDDDWWWWC 281  48 c[D₃W₅C] WWDDDWWWC 282  49 c[D₃W₅C] WWWDDDWWC 283  50 c[D₃W₅C] WWWWDDDWC 284  51 c[D₃W₅C] WDWDDWWWC 285  52 c[D₃W₅C] WDWWDDWWC 286  53 c[D₃W₅C] WDWWWDDWC 287  54 c[D₃W₅C] WDWWWWDDC 288  55 c[D₃W₅] DDDWWWWW 289  56 c[D₃W₅] DWDWWWWD 290  57 c[D₃W₅] DWWDWWWD 291  58 c[D₃W₅] DWWWDWWD 292  59 c[D₃W₅] DWWWWDWD 293  60 c[D₃W₅] DWWWWWDD 294  61 c[D₃W₅] DWDDWWWW 295  62 c[D₃W₅] DWWDDWWW 296  63 c[D₃W₅] DWWWDDWW 297  64 c[D₃W₅] DWWWWDDW 298  65 c[D₃W₅] WDDDWWWW 299  66 c[D₃W₅] WWDDDWWW 300  67 c[D₃W₅] WWWDDDWW 301  68 c[D₃W₅] WWWWDDDW 302  69 c[D₃W₅] WDWDDWWW 303  70 c[D₃W₅] WDWWDDWW 304  71 c[D₃W₅] WDWWWDDW 305  72 c[D₃W₅] WDWWWWDD 306  73 c[Gla₃W₅] GlaGlaGlaWWWWW 307  74 c[Gla₃W₅] GlaWGlaWWWWGla 308  75 c[Gla₃W₅] GlaWWGlaWWWGla 309  76 c[Gla₃W₅] GlaWWWGlaWWGla 310  77 c[Gla₃W₅] GlaWWWWGlaWGla 311  78 c[Gla₃W₅] GlaWWWWWGlaGla 312  79 c[Gla₃W₅] GlaWGlaGlaWWWW 313  80 c[Gla₃W₅] GlaWWGlaGlaWWW 314  81 c[Gla₃W₅] GlaWWWGlaGlaWW 315  82 c[Gla₃W₅] GlaWWWWGlaGlaW 316  83 c[Gla₃W₅] WGlaGlaGlaWWWW 317  84 c[Gla₃W₅] WWGlaGlaGlaWWW 318  85 c[Gla₃W₅] WWWGlaGlaGlaWW 319  86 c[Gla₃W₅] WWWWGlaGlaGlaW 320  87 c[Gla₃W₅] WGlaWGlaGlaWWW 321  88 c[Gla₃W₅] WGlaWWGlaGlaWW 322  89 c[Gla₃W₅] WGlaWWWGlaGlaW 323  90 c[Gla₃W₅] WGlaWWWWGlaGla 324  91 c[E₃W₄C] EEEWWWWC 325  92 c[E₃W₄C] EWEWWWEC 326  93 c[E₃W₄C] EWWEWWEC 327  94 c[E₃W₄C] EWWWEWEC 328  95 c[E₃W₄C] EWWWWEEC 329  96 c[E₃W₄C] EWEEWWWC 330  97 c[E₃W₄C] EWWEEWWC 331  98 c[E₃W₄C] EWWWEEWC 332  99 c[E₃W₄C] EWWWWEEC 333 100 c[E₃W₄C] WEEEWWWC 334 101 c[E₃W₄C] WWEEEWWC 335 102 c[E₃W₄C] WWWEEEWC 336 103 c[E₃W₄C] WWWWEEEC 337 104 c[E₃W₄C] WEWEEWWC 338 105 c[E₃W₄C] WEWWEEWC 339 106 c[E₃W₄C] WEWWWEEC 340 107 c[E₃W₄] EEEWWWW 341 108 c[E₃W₄] EWEWWWE 342 119 c[E₃W₄] EWWEWWE 343 110 c[E₃W₄] EWWWEWE 344 111 c[E₃W₄] EWWWWEE 345 112 c[E₃W₄] EWEEWWW 346 113 c[E₃W₄] EWWEEWW 347 114 c[E₃W₄] EWWWEEW 348 115 c[E₃W₄] EWWWWEE 349 116 c[E₃W₄] WEEEWWW 350 117 c[E₃W₄] WWEEEWW 351 118 c[E₃W₄] WWWEEEW 352 119 c[E₃W₄] WWWWEEE 353 120 c[E₃W₄] WEWEEWW 354 121 c[E₃W₄] WEWWEEW 355 122 c[E₃W₄] WEWWWEE 356 123 c[D₃W₄C] DDDWWWWC 357 124 c[D₃W₄C] DWDWWWDC 358 125 c[D₃W₄C] DWWDWWDC 359 126 c[D₃W₄C] DWWWDWDC 360 127 c[D₃W₄C] DWWWWDDC 361 128 c[D₃W₄C] DWDDWWWC 362 129 c[D₃W₄C] DWWDDWWC 363 130 c[D₃W₄C] DWWWDDWC 364 131 c[D₃W₄C] DWWWWDDC 365 132 c[D₃W₄C] WDDDWWWC 366 133 c[D₃W₄C] WWDDDWWC 367 134 c[D₃W₄C] WWWDDDWC 368 135 c[D₃W₄C] WWWWDDDC 369 136 c[D₃W₄C] WDWDDWWC 370 137 c[D₃W₄C] WDWWDDWC 371 138 c[D₃W₄C] WDWWWDDC 372 139 c[D₃W₄] DDDWWWW 373 140 c[D₃W₄] DWDWWWD 374 141 c[D₃W₄] DWWDWWD 375 142 c[D₃W₄] DWWWDWD 376 143 c[D₃W₄] DWWWWDD 377 144 c[D₃W₄] DWDDWWW 378 145 c[D₃W₄] DWWDDWW 379 146 c[D₃W₄] DWWWDDW 380 147 c[D₃W₄] DWWWWDD 381 148 c[D₃W₄] WDDDWWW 382 149 c[D₃W₄] WWDDDWW 383 150 c[D₃W₄] WWWDDDW 385 151 c[D₃W₄] WWWWDDD 386 152 c[D₃W₄] WDWDDWW 387 153 c[D₃W₄] WDWWDDW 388 154 c[D₃W₄] WDWWWDD 399 155 c[Gla₃W₄] GlaGlaGlaWWWW 400 156 c[Gla₃W₄] GlaWGlaWWWGla 401 157 c[Gla₃W₄] GlaWWGlaWWGla 402 158 c[Gla₃W₄] GlaWWWGlaWGla 403 159 c[Gla₃W₄] GlaWWWWGlaGla 404 160 c[Gla₃W₄] GlaWGlaGlaWWW 405 161 c[Gla₃W₄] GlaWWGlaGlaWW 406 162 c[Gla₃W₄] GlaWWWGlaGlaW 407 163 c[Gla₃W₄] GlaWWWWGlaGla 408 164 c[Gla₃W₄] WGlaGlaGlaWWW 409 165 c[Gla₃W₄] WWGlaGlaGlaWW 410 166 c[Gla₃W₄] WWWGlaGlaGlaW 411 167 c[Gla₃W₄] WWWWGlaGlaGla 412 168 c[Gla₃W₄] WGlaWGlaGlaWW 413 169 c[Gla₃W₄] WGlaWWGlaGlaW 414 170 c[Gla₃W₄] WGlaWWWGlaGla 415 171 c[(WE)₃WC] WEWEWEWC 416 172 c[(EW)₃WC] EWEWEWWC 417 173 c[(WD)₃WC] WDWDWDWC 418 174 c[(DW)₃WC] DWDWDWWC 419 175 c[(WGla)₃WC] WGlaWGlaWDWC 420 176 c[(GlaW)₃WC] DWDWDWDC 421 177 c[(WE)₄] WEWEWEWE 422 178 c[(EW)₄] EWEWEWEW 423 179 c[(WD)₄] WDWDWDWD 424 180 c[(DW)₄] DWDWDWDW 425 181 c[(WGla)₄] WGlaWGlaWGlaW 426 Gla 182 c[(GlaW)₄] GlaWGlaWGlaWG 427 laW 183 c[CW(EW)₄] CWEWEWEWEW 428 184 c[(WGla)₂WDWC] WGlaWGlaWDWC 429 185 c[(EW)₃EC] EWEWEWEC 430 186 c[(DW)₃DC] DWDWDWDC 431 187 c[E₅K]W₅C Cyclic: EEEEEK 432 (cyclic Tail: WWWWWC portion), 433 (Tail) 188 c[E₄K]W₅C Cyclic: EEEEK 434 (cyclic Tail: WWWWWC portion), 435 (Tail) 189 c[E₅K]W₄C Cyclic: EEEEEK 436 (cyclic Tail: WWWWC portion), 437 (Tail) 190 c[E₄K]W₄C Cyclic: EEEEK 438 (cyclic Tail: WWWWC portion), 439 (Tail) 191 c[E₅K]W₅ Cyclic: EEEEEK 440 (cyclic Tail: WWWWW portion), 441 (Tail) 192 c[E₄K]W₅ Cyclic: EEEEK 442 (cyclic Tail: WWWWW portion), 443 (Tail) 193 c[E₅K]W₄ Cyclic: EEEEEK 444 (cyclic Tail: WWWW portion), 445 (Tail) 194 c[E₄K]W₄ Cyclic: EEEEK 446 (cyclic Tail: WWWW portion), 447 (Tail) 195 c[D₅K]W₅C Cyclic: DDDDDK 448 (cyclic Tail: WWWWWC portion), 449 (Tail) 196 c[D₄K]W₅C Cyclic: DDDDK 450 (cyclic Tail: WWWWWC portion), 451 (Tail) 197 c[D₅K]W₄C Cyclic: DDDDDK 452 (cyclic Tail: WWWWC portion), 453 (Tail) 198 c[D₄K]W₄C Cyclic: DDDDK 454 (cyclic Tail: WWWWC portion), 455 (Tail) 199 c[D₅K]W₅ Cyclic: DDDDDK 456 (cyclic Tail: WWWWW portion), 457 (Tail) 200 c[D₄K]W₅ Cyclic: DDDDK 458 (cyclic Tail: WWWWW portion), 459 (Tail) 201 c[D₅K]W₄ Cyclic: DDDDDK 460 (cyclic Tail: WWWW portion), 461 (Tail) 202 c[D₄K]W₄ Cyclic: DDDDK 462 (cyclic Tail: WWWW portion), 463 (Tail) 203 c[Gla₅K]W₅C Cyclic: GlaGla 464 (cyclic GlaGlaGlaK portion), Tail: WWWWWC 465 (Tail) 204 c[Gla₄K]W₅C Cyclic: GlaGla 466 (cyclic GlaGlaK portion), Tail: WWWWWC 467 (Tail) 205 c[Gla₅K]W₄C Cyclic: GlaGla 468 (cyclic GlaGlaGlaK portion), Tail: WWWWC 469 (Tail) 206 c[Gla₄K]W₄C Cyclic: GlaGla 470 (cyclic GlaGlaK portion), Tail: WWWWC 471 (Tail) 207 c[Gla₅K]W₅ Cyclic: GlaGla 472 (cyclic GlaGlaGlaK portion), Tail: WWWWW 473 (Tail) 208 c[Gla₄K]W₅ Cyclic: GlaGla 474 (cyclic GlaGlaK portion), Tail: WWWWW 475 (Tail) 209 c[Gla₅K]W₄ Cyclic: GlaGla 476 (cyclic GlaGlaGlaK portion), Tail: WWWW 477 (Tail) 210 c[Gla₄K]W₄ Cyclic: GlaGla 478 (cyclic GlaGlaK portion), Tail: WWWW 479 (Tail) 211 c[E₅W₅C] EEEEEWWWWWC 480 212 c[E₄W₄C] EEEEWWWWC 481 213 c[(WE)₄CW] WEWEWEWECW 482 214 c[(WR)₄WC] WRWRWRWRWC 483

Production of Epitope-pHLIP® Peptide Compositions

To manufacture the constructs or compositions to decorate the cell surfaces of diseased cell, a variety of methods known in the art can be used, e.g.:

-   -   i) epitope synthesized and linked to the membrane non-inserting         part of pHLIP® peptide; or     -   ii) epitope synthesized as membrane non-inserting part of pHLIP®         as a single peptide; or     -   iii) epitope expressed as membrane non-inserting part of pHLIP®         fusion protein.

EXAMPLES

Examples are provided below to facilitate a more complete understanding of the invention. The following examples illustrate the exemplary modes of making and practicing the invention. However, the scope of the invention is not limited to specific embodiments disclosed in these Examples, which are for purposes of illustration only, since alternative methods can be utilized to obtain similar results.

Example 1: Tethering Small Molecule Epitope Di-nitrophenyl (DNP) to Cancer Cells by pHLIP® Promoted Cell Killing

Three different pHLIP® constructs were synthesized with a DNP—(O—(2,4-dinitrophenyl)hydroxylamine):

i) DNP-pHLIP®, where DNP-malemide was conjugated with a single Cys residue at the N-terminal of the pHLIP® peptide; ii) DNP-PEG4-pHLIP®, where DNP-PEG4-NHS was conjugated with a single Lys residue at the N-terminal of the pHLIP® peptide; and iii) DNP-PEG12-pHLIP®, where DNP-PEG12-NHS as conjugated with a single Lys residue at the N-terminal of pHLIP® peptide.

pHLIP® peptide with a single Cys residues used in the study for conjugation with DNP-malemide is the following: (ACDDQNPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______) pHLIP® peptide with single Lys residue and acetylated N-terminus used in the study for conjugation with DNP-PEG4-NHS and DNP-PEG12-NHS is the following: Ac-AKDDQNPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______)). Peptides were prepared by solid-phase synthesis. Progressions of coupling reactions and purifications were performed using reverse-phase HPLC (RP-HPLC) (the gradient: water and acetonitrile with 0.05% trifluoroacetic acid (TFA) followed by lyophilization. The purity and identity of the constructs were established by analytical RP-HPLC and surface-enhanced laser desorption/ionization time of flight (SELDI-TOF) mass spectroscopy, respectively. Constructs concentrations were calculated by absorbance at 280 nm using pHLIP® peptide extinction coefficient.

The key for induction of immunological response is a proper positioning of epitope at the surface of tumor cells, which was verified on 3-D tumor cancer cell culture (tumor spheroids). Briefly, a 2% agarose solution was made by dissolving in pH 7.4 PBS. 150 μL of the solution was pipetted into each well of a 48-well flat bottom tissue culture plate. After the agarose gel sufficiently settled (˜1 h), 150 μL of DMEM supplemented with 10% FBS and ciprofloxacin·HCl was added to each well. The covered plate was left in a humidified atmosphere at 37° C. and 5% CO₂ in cell culture incubator for 24 h. On the next day, the excess medium was removed from the agarose layer. HeLa cells (10,000 cells) in 200 μL of DMEM containing 2% matrigel were added into each well and incubated for 3-4 days to allow the formation of spheroids. Matrigel was dissolved on ice overnight and added in ice cold DMEM at a concentration of 2.5% (to obtain a final concentration of 2% once added to the wells). Then the mixture was heated to 37° C. before being combined with the cells. Tumor spheroids were incubated in 50 μL of PBS buffer, pH 6.0-6.5 containing 0-2 μM DNP-pHLIP®, DNP-PEG4-pHLIP® or DNP-PEG12-pHLIP® in a humidified atmosphere of 5% CO₂ at 37° C. for 30 min. After treatment, the spheroids were washed several times in 1 mL of PBS. Next, spheroids were treated with anti-DNP antibody labeled with 647 nm fluorescent dye at pH 7.4 followed by washing. Spheroids were also stained with DAPI to mark cell nucleus.

The spheroids were imaged using a fluorescent inverted confocal microscope. The representative images are shown in FIG. 6. The data clearly indicate that pHLIP® peptide positioned DNP epitope at the surface of cancer cells in 3-D cell culture, and the epitope was recognized by the corresponding antibody.

Images presented in FIG. 7 were obtained at high magnification to demonstrate that fluorescent signal from the antibody coincided with the fluorescent signal from DAPI, which stains DNA in cell nucleus. There were multiple focal planes in 3-D tumor spheroid and focus for DAPI signal and 647 nm fluorescent light were different, however an overlay between fluorescence from the antibody and DAPI fluorescence is clearly observed.

To establish a biological effect, the tumor speroids were treated with 5 μM of DNP-pHLIP®, DNP-PEG4-pHLIP® or DNP-PEG12-pHLIP® for 1 hour in PBS pH6.5, washed followed by incubation with anti-DNP antibody or human IgM antibody for 1 hr in PBS pH7.4. Then human serum with active complement and propidium iodine (PI) were added, washed and spheroids were imaged. Cell impermeable PI dye stains only dead (or dying) cells with the compromised membrane. Therefore presence of red color on FIG. 8 indicated that plasma membrane of cells was comrpomized by complement-mediated attack and that the cells were dying.

Example 2: Tethering Two Peptide Epitopes by pHLIP® to Cancer Cells to Bind Two Heads of Ig Antibody

To enhance performance of antibodies and enhance immune response, it is important to promote binding of both heads of IgG with 2 epitopes coupled to the same pHLIP® peptide (see, e.g., FIG. 5B). The pHLIP® peptide with 2 Lys residues (bold and underlined) (Ac-AKQNDDQNKPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______)) is conjugated with excess of NHS-PEG12-malemide and NHS-PEG24-malemide linkers, purified and, pHLIP-(PEG12)₂ is coupled with an HA peptide epitope (YPYDVPDYAGGGCA (SEQ ID NO: ______)). pHLIP® and HA peptides are prepared by solid-phase synthesis. Progressions of both coupling reactions and purifications are performed using reverse-phase HPLC (RP-HPLC) (the gradient: water and acetonitrile with 0.05% TFA) followed by lyophilization. The concentration of the construct is measured by absorbance at 280 nm.

PEG12 and PEG24 are be stretched for 5 nm and 10 nm, respectively. The six residues (QNDDQN (SEQ ID NO: ______)) between points of PEG conjugation to pHLIP® provides additional space of few nanometers, for example, from 5 to 25 nm, or, from about 10-15 nm. Thus, two epitopes at the single pHLIP® construct bind two heads of Ig antibody, since the distance between heads is 10-15 nm.

HeLa cancer cells in 2D and 3D cell culture are stained with (HA)₂-(PEG12)₂-pHLIP®, (HA)₂-(PEG24)₂-pHLIP®, HA-PEG12-pHLIP® and HA-PEG24-pHLIP®. Affinity of fluorescent antibody against HA peptide epitope is evaluated.

Example 3: Tethering CXCL10 Protein Chemokine Epitope by pHLIP® to Cancer Cells to Promote NK-Cells Binding

Two fusion proteins with 2 different tags (His and cMyc) are expressed and purified:

CXCL10-mucin-2x-Myc-pHLIP ® SEQ ID NO: 531 mnqtailicclifltlsgiqgvplsrtvrctcisisnqpvnprslekleii pasqfcprveiiatmkkkgekrclnpeskaiknllkavskerskrspgtfe kqigevkprttpaaggmdesvvlepeatgesssleptpssqeaqralgtsp elptgvtgssgtrlpptpkaqdggpvgtelfrvppvstaatwqssaphqpg pslwaeaktseapstqdpstqastasspapeenapsegqrvwgqgqsprpe nslereemgpvpahtdafqdwgpgsmahvsvvpvssegtpsrepvasgswt pkaeepihatmdpqrlgvlitpvpdaqaatrrqeqkliseedleqklisee dladdqnpwrayidllfptdtllldllw CXCL10-mucin-6x-His-pHLIP ® SEQ ID NO: 532 mnqtailicclifltlsgiqgvplsrtvrctcisisnqpvnprslekleii pasqfcprveiiatmkkkgekrclnpeskaiknllkavskerskrspgtfe kqigevkprttpaaggmdesvvlepeatgesssleptpssqeaqralgtsp elptgvtgssgtrlpptpkaqdggpvgtelfrvppvstaatwqssaphqpg pslwaeaktseapstqdpstqastasspapeenapsegqrvwgqgqsprpe nslereemgpvpahtdafqdwgpgsmahvsvvpvssegtpsrepvasgswt pkaeepihatmdpqrlgvlitpvpdaqaatrrqhhhhhhaddqnpwrayld llfptdtllldllw

Both fusion proteins are treated with HeLa or HeLa-GFP cancer cells at pH 6.0-6.5 followed by washing and applying NK-cells loaded with red fluorescent dye DiI (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine) for 30 min followed by gentle washing. Binding and adhesion of NK-cells to cancer cells decorated with CXCL10 chemokine pHLIP® constructs and non-decorated are compared under fluorescent microscope by analyzing green and red fluorescent signals coming from cancer cells and immune NK-cells, respectively.

pHLIP® Peptide-Mediated Epitope Tethering at Cell Surfaces: Summary I

The invention features compositions and methods for eliciting an immune response in a subject by administering to the subject a pHLIP® construct comprising an antibody recruiting molecule or an immune cell recruiting molecule. The antibody recruiting molecule or an immune cell recruiting molecule is linked to one or more pHLIP® peptides and wherein The construct increases the amount of antibody recruiting molecule or immune cell recruiting molecule on the surface of a diseased cell.

For example, the composition comprises the formula of:

Epitope-Linker-Pept

wherein “Epitope” is an antibody or immune cell recruiting molecule;

wherein “Linker” is a non-cleavable linker compound or a membrane non-inserting end of the pHLIP® peptide further comprises an amino acid extension;

wherein “Pept” is a pHLIP® peptide comprising the sequence

AXDDQNPWRAYLDLLFPTDTLLLDLLW (SEQ ID NO: ______) or

AXDQDNPWRAYLDLLFPTDTLLLDLLW (SEQ ID NO: ______), where “X” is a functional group, selected from a lysine, a cysteine, or an Azido-containing amino acid;

wherein each “—” is a covalent bond;

In some examples, the construct comprises an antibody recruiting molecule; in other examples, the construct comprises an immune cell recruiting molecule. Optionally, the construct comprises both an antibody recruiting molecule or an immune cell recruiting molecule

In some embodiments, 2 antibody recruiting molecules are linked to pHLIP® peptide. Such an exemplary construct and method is described below. For example, the composition or method includes a construct that comprises the formula of

Epitope1-Linker-Pept-Linker-Epitope1

wherein “Epitope1” is an antibody recruiting molecule;

wherein “Linker” is a polyethylene glycol linker;

wherein “Pept” is a pHLIP® peptide comprising the sequence

(SEQ ID NO:_) Ac-AKQNDDQNKPWRAYLDLLFPTDTLLLDLLWA or (SEQ ID NO:_) Ac-AKQNDNDNKPWRAYLDLLFPTDTLLLDLLWA or (SEQ ID NO:_) ACQNDDQNCPWRAYLDLLFPTDTLLLDLLWA or (SEQ ID NO:_) ACQNDNDNCPWRAYLDLLFPTDTLLLDLLWA

wherein each “—” is a covalent bond.

As described above, exemplary recruiting molecules include one or more epitopes. For example, the epitope comprises a peptide with a length less than 50 amino acids.

The method of claim 1, wherein said antibody recruiting molecule or immune cell recruiting molecule comprises an epitope. In examples, the epitope comprises a peptide with a length less than 50 amino acids, e.g., the epitope comprises a length of between 5 to 20 amino acids. An exemplary epitope comprises an HA peptide. For example, the peptide comprises the amino acid sequence of YPYDVPDYA (SEQ ID NO: ______). Additional examples of epitopes include QVSHWVSGLAEGSFG (SEQ ID NO: ______), LSHTSGRVEGSVSLL (SEQ ID NO: ______), QMWAPQWGPD (SEQ ID NO: ______); MASMTGGQQMG (SEQ ID NO: 4); EQKLISEEDL (SEQ ID NO: 5); YTDIEMNRLGK (SEQ ID NO: 7); KETAAAKFERQHMDS (SEQ ID NO: 8); GKPIPNPLLGLDST (SEQ ID NO: 9); DYKDDDDK (SEQ ID NO: 10); GAPVPYPDPLEPR (SEQ ID NO: 11); HHHHHH (SEQ ID NO: 12); TKENPRSNQEESYDDNES (SEQ ID NO: 13); WSHPQFEK (SEQ ID NO: 14); or PDRVRAVSHWSS (SEQ ID NO: 15).

In examples, an epitope comprises a protein epitope with a length of 200 or less amino acids. For example, the protein epitope comprises a cytokine such as an interleukin (IL), e.g., IL-1, IL-2, IL-6, IL-7, IL-12, or IL-17. In some embodiments, the cytokine comprises tumor necrosis factor (TNF). In some some embodiments, the cytokine comprises a chemokine (CXC). Examples of chemokines include CXCL9, CXL10, or CXL11. For example, the chemokine comprises CXCL10 comprises the amino acid sequence:

(SEQ ID NO: ) MNQTAILICCLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRSLEKLEII PASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKERSKRSP.

In yet other examples, the epitope comprises a small molecule. For example, the small molecule comprises a dinitrophenyl (DNP) or a derivative thereof.

The methods are useful to methods for eliciting an immune response in a subject. This clinically beneficial effect is accomplished by the pHLIP® construct that increases the amount of antibody recruiting molecule or immune cell recruiting molecule on the surface of a diseased cell. For example, the diseased cell comprises a tumor cell. In another example, the diseased cell comprises a cell in inflamed tissue.

Also within the invention is a composition comprising an antibody or immune cell recruiting molecule linked to one or more pHLIP® peptides by a non-cleavable linker compound. A composition comprising an epitope linked to one or more pHLIP® peptides, wherein the epitope is a protein epitope and is an extension of the non-inserting end of the pHLIP® peptide is also within the invention. For example, the non-inserting end of the pHLIP® peptide further comprises an amino acid extension, wherein the extension comprises a protein epitope. In another aspect, the invention encompasses a composition comprising an epitope linked to one or more pHLIP® peptides, wherein the epitope and the pHLIP® peptide are part of a single fusion construct.

In the methods or compositions, the pHLIP® construct comprises the formula of Epitope-Linker-Peptide, wherein Peptide is a pHLIP® peptide comprising the sequence AXDDQNPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______) or AXDQDNPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______), where “X” is a functional group, selected from a lysine, a cysteine, or an Azido-containing amino acid, wherein Linker is a linker or an extension of the pHLIP® peptide, and wherein each “—” is a covalent bond.

An exemplary composition comprises the formula of Epitope-Linker-Peptide, wherein Peptide is a pHLIP® peptide comprising the sequence AXDDQNPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______) or AXDQDNPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______), where X is a functional group, selected from a lysine, a cysteine, or an Azido-containing amino acid, and wherein Linker is a linker or an extension of the pHLIP® peptide, and wherein each “—” is a covalent bond. In some examples, two epitopes are linked to a single pHLIP® peptide.

As described above, the construct may comprise the formula of Epitope2-Linker2-Peptide, wherein Peptide is a pHLIP® peptide comprising the sequence AX(Z)nXPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______), wherein X is a functional group, selected from a lysine, a cysteine, an Azido-containing amino acid, or others, wherein Z comprises indicates any amino acid residue, wherein n is any integer between 1 and 10, wherein Linker is a linker or an extension of the pHLIP® peptide, and each “—” is a covalent bond. In another example, the composition or construct comprises the formula of Epitope2-Linker2-Pept, wherein “Pept” is a pHLIP® peptide comprising the sequence AX(Z)nXPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______), where X is a functional group, selected from a lysine, a cysteine, an Azido-containing amino acid, wherein Z indicates any amino acid residue, wherein n is any integer between and including 1 and 10, wherein Linker is a linker or an extension of the pHLIP® peptide, and wherein each “—” is a covalent bond.

A method of inducing an immune response in a diseased tissue in a subject, which method comprises the step of administering to a subject a composition comprising an epitope and a pHLIP® peptide is also within the invention. For example, the subject comprises a solid tumor or the subject comprises an inflamed tissue. The pHLIP® compositions or constructs are administered in a variety of clinically-acceptable methods, e.g, the composition is injected directly into a diseased tissue tumor mass. In another example, the composition is systemically administered. The method is associated with numerous advantages, e.g., the biological effect of the composition in eliciting or promoting an antigen-specific (epitope-specific) immune response is at least 20% greater than that delivered in the absence of said composition. The response may be at least 25, 50, 75, 90% and even 2-fold, 3-fold, 5-fold, 10-fold or more greater than that delivered in the absence of pHLIP® composition or construct. Another significant advantage is that the composition targets preferentially to a diseased tissue compared to a healthy tissue, thereby minimizing damage to said healthy tissue.

Also within the invention is a method for promoting an immune response in a subject, comprising administering to a subject the pHLIP® compositions and constructs described herein, wherein the method comprises placement of the epitope on tumor cell or a cell in inflamed tissue of said subject.

pHLIP® Peptide-Mediated Epitope Tethering at Cell Surfaces: Summary II

Exemplary pHLIP® compositions comprise an epitope and a pHLIP® peptide.

In one example, the composition comprises the formula of

Epitope-Linker-Pept

wherein “Epitope” is an antibody or immune cell recruiting molecule; wherein “Linker” is a non-cleavable linker compound or a membrane non-inserting end of the pHLIP® peptide further comprises an amino acid extension; wherein “Pept” is a pHLIP® peptide comprising the sequence AXDDQNPWRAYLDLLFPTDTLLLDLLW (SEQ ID NO: ______) or AXDQDNPWRAYLDLLFPTDTLLLDLLW (SEQ ID NO: ______), where “X” is a functional group, selected from a lysine, a cysteine, or an Azido-containing amino acid; wherein each “—” is a covalent bond.

Antibody Recruitment

In preferred embodiments, the epitope is an antibody recruiting molecule. For example, 2 antibody recruiting molecules are linked to pHLIP® peptide. An example of such a composition for recruiting antibodies includes a composition comprising the formula of

Epitope1-Linker-Pept-Linker-Epitope1

wherein “Epitope1” is an antibody recruiting molecule; wherein “Linker” is a polyethylene glycol linker; wherein “Pept” is a pHLIP® peptide comprising the sequence

(SEQ ID NO:   ) Ac-AKQNDDQNKPWRAYLDLLFPTDTLLLDLLWA or (SEQ ID NO:   ) Ac-AKQNDNDNKPWRAYLDLLFPTDTLLLDLLWA or (SEQ ID NO:   ) ACQNDDQNCPWRAYLDLLFPTDTLLLDLLWA or (SEQ ID NO:   ) ACQNDNDNCPWRAYLDLLFPTDTLLLDLLWA wherein each “—” is a covalent bond;

For example, an epitope comprises a peptide with a length less than 50 amino acids, e.g., a length of between 5 to 20 amino acids. An exemplary epitope comprises an HA peptide, e.g., the peptide comprises the amino acid sequence of YPYDVPDYA (SEQ ID NO: ______).

Other epitopes include the following peptides: QVSHWVSGLAEGSFG (SEQ ID NO: ______), LSHTSGRVEGSVSLL (SEQ ID NO: ______), QMWAPQWGPD (SEQ ID NO: ______); MASMTGGQQMG (SEQ ID NO: 4); EQKLISEEDL (SEQ ID NO: 5); KETAAAKFERQHMDS (SEQ ID NO: 8); GKPIPNPLLGLDST (SEQ ID NO: 9); DYKDDDDK (SEQ ID NO: 10); GAPVPYPDPLEPR (SEQ ID NO: 11); HHHHHH (SEQ ID NO: 12); TKENPRSNQEESYDDNES (SEQ ID NO: 13); WSHPQFEK (SEQ ID NO: 14); and/or PDRVRAVSHWSS (SEQ ID NO: 15).

In some examples, the epitope comprises a small molecule such as dinitrophenyl (DNP) or a derivative thereof.

Immune Cell Recruitment

In some examples the epitope is an immune cell recruiting molecule.

An exemplary composition, e.g. for recruiting immune cells, comprises the formula of

Epitope2-Pept,

wherein “Epitope2” is an immune cell recruiting molecule; wherein “Pept” is a pHLIP® peptide comprising the sequence

(SEQ ID NO: ) ADDQNPWRAYLDLLFPTDTLLLDLLW; wherein “—” is a covalent bond. In such examples, the epitope comprises a protein epitope with a length of 350 or less amino acids. An exemplary protein epitope comprises a cytokine. For example, the cytokine comprises an interleukin (IL) such as IL-2, IL-6, IL-7, or IL-12. In other examples, the cytokine comprises tumor necrosis factor (TNF).

In some embodiments, the cytokine comprises a chemokine such as CXCL9, CXCL10, or CXCL11. For example, chemokine comprises CXCL10 comprising the amino acid sequence:

(SEQ ID NO: ) MNQTAILICCLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRSLEKLEII PASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKERSKRSP.

Compositions with Amino Acid Extension to pHLIP® Peptide

In some aspect, the invention features compositions, constructs, and methods comprising an epitope wherein the membrane non-inserting end of the pHLIP® peptide further comprises an amino acid extension. For example, the composition comprises an epitope and pHLIP® peptide comprises a fusion protein. For example, fusion protein comprises an epitope and a pHLIP® peptide. In other examples, a composition comprises an epitope linked to one or more pHLIP® peptides by a non-cleavable linker compound.

A variety of linkers may be used. For example, the linker is a chemical polymer, e.g., polyethylene glycol. In other examples, the linker is a biopolymer. Exemplary linkers include mucin domain, dextran, cellulose, chitin or starch.

Methods of Treatment

The invention also includes a method of inducing an immune response in a diseased tissue in a subject, comprising administering to a subject a composition comprising an epitope and a pHLIP® peptide. For example, the subject comprises a solid tumor. Alternatively, the subject comprises an inflamed tissue. In some cases, both conditions are present in the subject.

The subject is treated using a variety of clinically acceptable procedures, e.g, the composition is injected directly into a diseased tissue tumor mass. In another example, the composition is systemically administered. As described above, an advantage of the methods is that a biological effect of said composition is at least 20% or more greater than that delivered in the absence of said composition. Another advantage that contributes to the clinical safety and efficacy is that the composition targets preferentially to a diseased tissue compared to a healthy tissue, thereby minimizing damage to healthy tissue.

An exemplary method for promoting an immune response in a subject is carried out by administering to a subject the compositions and constructs described above. Such methods comprise, e.g., lead to, the placement of the epitope(s) on tumor cell or a cell in inflamed tissue of the subject. The increase amount or concentration of the epitope on the sureface of the tumor cell or cell in an inflamed tissue leads to a more robust immune response, e.g., antibody-binding or immune cell binding, and subsequent killing and/or elimination of the diseased (or otherwise undesirable) cell. For example, the diseased cell comprises a tumor cell or a cell in inflamed tissue.

General Definitions

Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in cell culture, molecular genetics, and biochemistry).

As used herein, the term “about” in the context of a numerical value or range means ±10% of the numerical value or range recited or claimed, unless the context requires a more limited range.

In the descriptions above and in the claims, phrases such as “at least one of” or “one or more of” may occur followed by a conjunctive list of elements or features. The term “and/or” may also occur in a list of two or more elements or features. Unless otherwise implicitly or explicitly contradicted by the context in which it is used, such a phrase is intended to mean any of the listed elements or features individually or any of the recited elements or features in combination with any of the other recited elements or features. For example, the phrases “at least one of A and B;” “one or more of A and B;” and “A and/or B” are each intended to mean “A alone, B alone, or A and B together.” A similar interpretation is also intended for lists including three or more items. For example, the phrases “at least one of A, B, and C;” “one or more of A, B, and C;” and “A, B, and/or C” are each intended to mean “A alone, B alone, C alone, A and B together, A and C together, B and C together, or A and B and C together.” In addition, use of the term “based on,” above and in the claims is intended to mean, “based at least in part on,” such that an unrecited feature or element is also permissible.

It is understood that where a parameter range is provided, all integers within that range, and tenths thereof, are also provided by the invention. For example, “0.2-5 mg” is a disclosure of 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg etc. up to and including 5.0 mg.

A small molecule is a compound that is less than 2000 daltons in mass. The molecular mass of the small molecule is preferably less than 1000 daltons, more preferably less than 600 daltons, e.g., the compound is less than 500 daltons, 400 daltons, 300 daltons, 200 daltons, or 100 daltons.

As used herein, an “isolated” or “purified” nucleic acid molecule, polynucleotide, polypeptide, or protein, is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. Purified compounds are at least 60% by weight (dry weight) the compound of interest. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight the compound of interest. For example, a purified compound is one that is at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% (w/w) of the desired compound by weight. Purity is measured by any appropriate standard method, for example, by column chromatography, thin layer chromatography, or high-performance liquid chromatography (HPLC) analysis. A purified or isolated polynucleotide (ribonucleic acid (RNA) or deoxyribonucleic acid (DNA)) is free of the genes or sequences that flank it in its naturally-occurring state. Purified also defines a degree of sterility that is safe for administration to a human subject, e.g., lacking infectious or toxic agents. A purified or isolated polynucleotide (ribonucleic acid (RNA) or deoxyribonucleic acid (DNA)) is free of the genes or sequences that flank it in its naturally-occurring state. A purified or isolated polypeptide is free of the amino acids or sequences that flank it in its naturally-occurring state.

Similarly, by “substantially pure” is meant a nucleotide or polypeptide that has been separated from the components that naturally accompany it. Typically, the nucleotides and polypeptides are substantially pure when they are at least 60%, 70%, 80%, 90%, 95%, or even 99%, by weight, free from the proteins and naturally-occurring organic molecules with they are naturally associated.

The term “alkyl,” by itself or as part of another substituent, means, unless otherwise stated, a non-cyclic straight (i.e., unbranched) or branched chain, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e., C₁-C₁₀ means one to ten carbons). Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, (cyclohexyl)methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (—O—).

The term “alkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, —CH₂CH₂CH₂CH₂—. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms. A “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.

The term “heteroalkyl,” by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, consisting of at least one carbon atom and at least one heteroatom (e.g. selected from the group consisting of O, N, P, S, Se and Si, and wherein the nitrogen, selenium, and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized). The heteroatom(s) O, N, P, S, Se, and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Examples include, but are not limited to: —CH₂—CH₂—O—CH₃, —CH₂—CH₂—NH—CH₃, —CH₂—CH₂—N(CH₃)—CH₃, —CH₂—S—CH₂—CH₃, —CH₂—CH₂, —S(O)—CH₃, —CH₂—CH₂—S(O)₂—CH₃, —CH═CH—O—CH₃, —Si(CH₃)₃, —CH₂—CH═N—OCH₃, —CH═CH—N(CH₃)—CH₃, —O—CH₃, —O—CH—₂—CH₃, and —CN. Up to two heteroatoms may be consecutive, such as, for example, —CH₂—NH—OCH₃.

Similarly, the term “heteroalkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, —CH₂—CH₂—S—CH₂—CH₂— and —CH₂—S—CH₂—CH₂—NH—CH₂—. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula —C(O)₂R′— represents both —C(O)₂R′— and —R′C(O)₂—. As described above, heteroalkyl groups, as used herein, include those groups that are attached to the remainder of the molecule through a heteroatom, such as —C(O)R′, —C(O)NR′, —NR′R″, —OR′, —SeR′, —SR′, and/or —SO₂R′. Where “heteroalkyl” is recited, followed by recitations of specific heteroalkyl groups, such as —NR′R″ or the like, it will be understood that the terms heteroalkyl and —NR′R″ are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as —NR′R″ or the like.

The terms “cycloalkyl” and “heterocycloalkyl,” by themselves or in combination with other terms, mean, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl,” respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. A “cycloalkylene” and a “heterocycloalkylene,” alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively.

The term “aryl” means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently. A fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring. The term “heteroaryl” refers to aryl groups (or rings) that contain from one to four heteroatoms (e.g. selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized). Thus, the term “heteroaryl” includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring). A 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Likewise, a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. And a 6,5-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring. A heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. An “arylene” and a “heteroarylene,” alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively.

A fused ring heterocyloalkyl-aryl is an aryl fused to a heterocycloalkyl. A fused ring heterocycloalkyl-heteroaryl is a heteroaryl fused to a heterocycloalkyl. A fused ring heterocycloalkyl-cycloalkyl is a heterocycloalkyl fused to a cycloalkyl. A fused ring heterocycloalkyl-heterocycloalkyl is a heterocycloalkyl fused to another heterocycloalkyl. Fused ring heterocycloalkyl-aryl, fused ring heterocycloalkyl-heteroaryl, fused ring heterocycloalkyl-cycloalkyl, or fused ring heterocycloalkyl-heterocycloalkyl may each independently be unsubstituted or substituted with one or more of the substituents described herein. Spirocyclic rings are two or more rings wherein adjacent rings are attached through a single atom. The individual rings within spirocyclic rings may be identical or different. Individual rings in spirocyclic rings may be substituted or unsubstituted and may have different substituents from other individual rings within a set of spirocyclic rings. Possible substituents for individual rings within spirocyclic rings are the possible substituents for the same ring when not part of spirocyclic rings (e.g., substituents for cycloalkyl or heterocycloalkyl rings). Spirocylic rings may be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterocycloalkylene and individual rings within a spirocyclic ring group may be any of the immediately previous list, including having all rings of one type (e.g. all rings being substituted heterocycloalkylene wherein each ring may be the same or different substituted heterocycloalkylene). When referring to a spirocyclic ring system, heterocyclic spirocyclic rings means a spirocyclic rings wherein at least one ring is a heterocyclic ring and wherein each ring may be a different ring. When referring to a spirocyclic ring system, substituted spirocyclic rings means that at least one ring is substituted and each substituent may optionally be different.

Each of the above terms (e.g., “alkyl,” “heteroalkyl,” “aryl,” and “heteroaryl”) includes both substituted and unsubstituted forms of the indicated radical.

The transitional term “comprising,” which is synonymous with “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. By contrast, the transitional phrase “consisting of” excludes any element, step, or ingredient not specified in the claim. The transitional phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps “and those that do not materially affect the basic and novel characteristic(s)” of the claimed invention.

The terms “subject,” “patient,” “individual,” and the like as used herein are not intended to be limiting and can be generally interchanged. That is, an individual described as a “patient” does not necessarily have a given disease, but may be merely seeking medical advice.

As used herein, the singular forms “a,” “an,” and “the” include the plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a disease,” “a disease state”, or “a nucleic acid” is a reference to one or more such embodiments, and includes equivalents thereof known to those skilled in the art and so forth.

As used herein, “treating” encompasses, e.g., inhibition, regression, or stasis of the progression of a disorder. Treating also encompasses the prevention or amelioration of any symptom or symptoms of the disorder. As used herein, “inhibition” of disease progression or a disease complication in a subject means preventing or reducing the disease progression and/or disease complication in the subject.

As used herein, a “symptom” associated with a disorder includes any clinical or laboratory manifestation associated with the disorder, and is not limited to what the subject can feel or observe.

As used herein, “effective” when referring to an amount of a therapeutic compound refers to the quantity of the compound that is sufficient to yield a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this disclosure.

An epitope is a molecular region of an antigen capable of eliciting an immune response and of combining with a specific antibody or immune cell produced by such a response. An epitope is also know as an antigenic determinant. For example, an epitope is a part of an antigen molecule to which an antibody attaches or to which an immune cell attaches.

As used herein, the term “cancer” refers to all types of cancer, neoplasm or malignant tumors found in mammals, including leukemias, lymphomas, melanomas, neuroendocrine tumors, carcinomas and sarcomas. Exemplary cancers that may be treated with a compound, pharmaceutical composition, or method provided herein include lymphoma (cutaneous T-cell lymphoma), sarcoma, bladder cancer, bone cancer, brain tumor, cervical cancer, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, myeloma, thyroid cancer, leukemia, prostate cancer, breast cancer (e.g. triple negative, ER positive, ER negative, chemotherapy resistant, herceptin resistant, HER2 positive, doxorubicin resistant, tamoxifen resistant, ductal carcinoma, lobular carcinoma, primary, metastatic), ovarian cancer, pancreatic cancer, liver cancer (e.g., hepatocellular carcinoma), lung cancer (e.g. non-small cell lung carcinoma, squamous cell lung carcinoma, adenocarcinoma, large cell lung carcinoma, small cell lung carcinoma, carcinoid, sarcoma), glioblastoma multiforme, glioma, melanoma, prostate cancer, castration-resistant prostate cancer, breast cancer, triple negative breast cancer, glioblastoma, ovarian cancer, lung cancer, squamous cell carcinoma (e.g., head, neck, or esophagus), colorectal cancer, leukemia, acute myeloid leukemia, lymphoma, B cell lymphoma, or multiple myeloma. Additional examples include, cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, esophagus, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus or Medulloblastoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, Paget's Disease of the Nipple, Phyllodes Tumors, Lobular Carcinoma, Ductal Carcinoma, cancer of the pancreatic stellate cells, cancer of the hepatic stellate cells, or prostate cancer.

By, “small molecule” may be referred to broadly as an organic, inorganic or organometallic compound with a low molecular weight compound (e.g., a molecular weight of less than about 2,000 Da or less than about 1,000 Da). The small molecule may have a molecular weight of less than about 2,000 Da, a molecular weight of less than about 1,500 Da, a molecular weight of less than about 1,000 Da, a molecular weight of less than about 900 Da, a molecular weight of less than about 800 Da, a molecular weight of less than about 700 Da, a molecular weight of less than about 600 Da, a molecular weight of less than about 500 Da, a molecular weight of less than about 400 Da, a molecular weight of less than about 300 Da, a molecular weight of less than about 200 Da, a molecular weight of less than about 100 Da, or a molecular weight of less than about 50 Da.

Small molecules are organic or inorganic. Exemplary organic small molecules include, but are not limited to, aliphatic hydrocarbons, alcohols, aldehydes, ketones, organic acids, esters, mono- and disaccharides, aromatic hydrocarbons, amino acids, and lipids. Exemplary inorganic small molecules comprise trace minerals, ions, free radicals, and metabolites. Alternatively, small molecules can be synthetically engineered to consist of a fragment, or small portion, or a longer amino acid chain to fill a binding pocket of an enzyme. Typically small molecules are less than one kilodalton.

As used herein, the term “stereoisomers” refers to compounds made up of the same atoms having the same bond order but having different three-dimensional arrangements of atoms that are not interchangeable. The three-dimensional structures are called configurations. As used herein, the term “enantiomers” refers to two stereoisomers that are non-superimposable mirror images of one another. As used herein, the term “optical isomer” is equivalent to the term “enantiomer”. As used herein the term “diastereomer” refers to two stereoisomers which are not mirror images but also not superimposable. The terms “racemate”, “racemic mixture” or “racemic modification” refer to a mixture of equal parts of enantiomers. The term “chiral center” refers to a carbon atom to which four different groups are attached. Choice of the appropriate chiral column, eluent, and conditions necessary to effect separation of the pair of enantiomers is well known to one of ordinary skill in the art using standard techniques (see e.g. Jacques, J. et al., “Enantiomers, Racemates, and Resolutions”, John Wiley and Sons, Inc. 1981).

As used herein, “pharmaceutically acceptable” carrier or excipient refers to a carrier or excipient that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio. It can be, e.g., a pharmaceutically acceptable solvent, suspending agent or vehicle, for delivering the instant compounds to the subject.

Examples are provided below to facilitate a more complete understanding of the invention. The following examples illustrate the exemplary modes of making and practicing the invention. However, the scope of the invention is not limited to specific embodiments disclosed in these Examples, which are for purposes of illustration only, since alternative methods can be utilized to obtain similar results.

“Percentage of sequence identity” is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

The term “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identity over a specified region, e.g., of an entire polypeptide sequence or an individual domain thereof), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using a sequence comparison algorithm or by manual alignment and visual inspection. Such sequences that are at least about 80% identical are said to be “substantially identical.” In some embodiments, two sequences are 100% identical. In certain embodiments, two sequences are 100% identical over the entire length of one of the sequences (e.g., the shorter of the two sequences where the sequences have different lengths). In various embodiments, identity may refer to the complement of a test sequence. In some embodiments, the identity exists over a region that is at least about 10 to about 100, about 20 to about 75, about 30 to about 50 amino acids or nucleotides in length. In certain embodiments, the identity exists over a region that is at least about 50 amino acids in length, or more preferably over a region that is 100 to 500, 100 to 200, 150 to 200, 175 to 200, 175 to 225, 175 to 250, 200 to 225, 200 to 250 or more amino acids in length.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. In various embodiments, when using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A the “comparison window” refers to a segment of any one of the number of contiguous positions (e.g., least about 10 to about 100, about 20 to about 75, about 30 to about 50, 100 to 500, 100 to 200, 150 to 200, 175 to 200, 175 to 225, 175 to 250, 200 to 225, 200 to 250) in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. In various embodiments, a comparison window is the entire length of one or both of two aligned sequences. In some embodiments, two sequences being compared different lengths, and the comparison window is the entire length of the longer or the shorter of the two sequences. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al., eds. 1995 supplement)).

In various embodiments, an algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990), respectively. BLAST and BLAST 2.0 may be used, with the parameters described herein, to determine percent sequence identity for nucleic acids and proteins. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information, as known in the art. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=−4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=−4, and a comparison of both strands.

Other Embodiments

While the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. All United States patents and published or unpublished United States patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. Genbank and NCBI submissions indicated by accession number cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims. 

What is claimed is:
 1. A method of eliciting an immune response in a subject comprising administering to said subject a pHLIP® construct comprising an antibody recruiting molecule or an immune cell recruiting molecule linked to one or more pHLIP® peptides, wherein said construct increases the amount of said antibody or immune cell recruiting molecule on the surface of a diseased cell.
 2. The method of claim 1, wherein said antibody recruiting molecule or said immune cell recruiting molecule comprises an epitope.
 3. The composition of claim 1, wherein said construct comprises the formula of Epitope-Linker-Pept wherein “Epitope” is an antibody or immune cell recruiting molecule; wherein “Linker” is a non-cleavable linker compound or a membrane non-inserting end of the pHLIP® peptide further comprises an amino acid extension; wherein “Pept” is a pHLIP® peptide comprising the sequence AXDDQNPWRAYLDLLFPTDTLLLDLLW (SEQ ID NO: ______) or AXDQDNPWRAYLDLLFPTDTLLLDLLW (SEQ ID NO: ______), where “X” is a functional group, selected from a lysine, a cysteine, or an Azido-containing amino acid; wherein each “—” is a covalent bond.
 4. The method of claim 1, wherein said construct comprises an antibody recruiting molecule
 5. The method of claim 4, wherein 2 antibody recruiting molecules are linked to pHLIP® peptide.
 6. The method of claim 1, wherein said construct comprises the formula of Epitope 1-Linker-Pept-Linker-Epitope1 wherein “Epitope1” is an antibody recruiting molecule; wherein “Linker” is a polyethylene glycol linker; wherein “Pept” is a pHLIP® peptide comprising the sequence (SEQ ID NO:_) Ac-AKQNDDQNKPWRAYLDLLFPTDTLLLDLLWA or (SEQ ID NO:_) Ac-AKQNDNDNKPWRAYLDLLFPTDTLLLDLLWA or (SEQ ID NO:_) ACQNDDQNCPWRAYLDLLFPTDTLLLDLLWA or (SEQ ID NO:_) ACQNDNDNCPWRAYLDLLFPTDTLLLDLLWA

wherein each “—” is a covalent bond.
 7. The method of claim 2, wherein said epitope comprises a peptide with a length less than 50 amino acids.
 8. The method of claim 1, wherein said diseased cell comprises a tumor cell.
 9. The method of claim 1, wherein said diseased cell comprises a cell in inflamed tissue.
 10. The method of claim 1, wherein said antibody recruiting molecule or immune cell recruiting molecule comprises an epitope.
 11. The method of claim 2, wherein said epitope comprises a peptide with a length less than 50 amino acids.
 12. The method of claim 2, wherein said epitope comprises a length of between 5 to 20 amino acids.
 13. The method of claim 2, wherein said epitope is a HA peptide.
 14. The method of claim 12, wherein said peptide comprises the amino acid sequence of YPYDVPDYA (SEQ ID NO: ______).
 15. The method of claim 2, wherein said epitope is selected from the group consisting of QVSHWVSGLAEGSFG (SEQ ID NO: ______), LSHTSGRVEGSVSLL (SEQ ID NO: ______), QMWAPQWGPD (SEQ ID NO: ______); MASMTGGQQMG (SEQ ID NO: 4); EQKLISEEDL (SEQ ID NO: 5); YTDIEMNRLGK (SEQ ID NO: 7); KETAAAKFERQHMDS (SEQ ID NO: 8); GKPIPNPLLGLDST (SEQ ID NO: 9); DYKDDDDK (SEQ ID NO: 10); GAPVPYPDPLEPR (SEQ ID NO: 11); HHHHHH (SEQ ID NO: 12); TKENPRSNQEESYDDNES (SEQ ID NO: 13); WSHPQFEK (SEQ ID NO: 14); and PDRVRAVSHWSS (SEQ ID NO: 15).
 16. The method of claim 2, wherein said epitope comprises a protein epitope with a length of 200 or less amino acids.
 17. The method of claim 16, wherein said protein epitope comprises a cytokine.
 18. The method of claim 17, wherein said cytokine comprises an interleukin (IL).
 19. The method of claim 18, wherein said interleukin comprises IL-1, IL-2, IL-6, IL-7, IL-12, and IL-17.
 20. The method of claim 17, wherein said cytokine comprises tumor necrosis factor (TNF).
 21. The method of claim 17, wherein said cytokine comprises a chemokine (CXC).
 22. The method of claim 21, wherein said chemokine is CXCL9, CXL10, or CXL11.
 23. The method of claim 21, wherein said chemokine comprises CXCL10 comprising the amino acid sequence: (SEQ ID NO: ) MNQTAILICCLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRSLEKLEII PASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKERSKRSP.


24. The method of claim 2, wherein said epitope comprises a small molecule.
 25. The method of claim 24, wherein said small molecule comprises a dinitrophenyl (DNP) or a derivative thereof.
 26. A composition comprising an antibody or immune cell recruiting molecule linked to one or more pHLIP® peptides by a non-cleavable linker compound.
 27. A composition comprising an epitope linked to one or more pHLIP® peptides, wherein the epitope is a protein epitope and is an extension of the non-inserting end of the pHLIP® peptide.
 28. The composition of claim 27, wherein said extension comprises a peptide epitope.
 29. A composition comprising an epitope linked to one or more pHLIP® peptides, wherein the epitope and the pHLIP® peptide are part of a single fusion construct or fusion protein.
 30. The method of claim 1, wherein said construct comprises the formula of Epitope-Linker-Peptide, wherein Peptide is a pHLIP® peptide comprising the sequence AXDDQNPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______) or AXDQDNPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______), where “X” is a functional group, selected from a lysine, a cysteine, or an Azido-containing amino acid, wherein Linker is a linker or an extension of the pHLIP® peptide, and wherein each “—” is a covalent bond.
 31. A composition comprising the formula of Epitope-Linker-Peptide, wherein Peptide is a pHLIP® peptide comprising the sequence AXDDQNPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______) or AXDQDNPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______), where X is a functional group, selected from a lysine, a cysteine, or an Azido-containing amino acid, and wherein Linker is a linker or an extension of the pHLIP® peptide, and wherein each — is a covalent bond.
 32. The composition of claim 31, wherein two epitopes are linked to a single pHLIP® peptide.
 33. The method of claim 1, wherein said construct comprises the formula of Epitope₂-Linker₂-Peptide, wherein Peptide is a pHLIP® peptide comprising the sequence AX(Z)_(n)XPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______), wherein X is a functional group, selected from a lysine, a cysteine, an Azido-containing amino acid, or others, wherein Z comprises indicates any amino acid residue, wherein n is any integer between 1 and 10, wherein Linker is a linker or an extension of the pHLIP® peptide, and each “—” is a covalent bond.
 34. The composition of claim 33, wherein said composition comprising the formula of Epitope₂-Linker₂-Pept, wherein “Pept” is a pHLIP® peptide comprising the sequence AX(Z)_(n)XPWRAYLDLLFPTDTLLLDLLWA (SEQ ID NO: ______), where X is a functional group, selected from a lysine, a cysteine, an Azido-containing amino acid, wherein Z indicates any amino acid residue, wherein n is any integer between and including 1 and 10, wherein Linker is a linker or an extension of the pHLIP® peptide, and wherein each — is a covalent bond.
 35. A method of inducing an immune response in a diseased tissue in a subject, comprising administering to a subject a composition comprising an epitope and a pHLIP® peptide.
 36. The method of claim 35, wherein said subject comprises a solid tumor.
 37. The method of claim 35, wherein said subject comprises an inflamed tissue.
 38. The method of claim 35, wherein said composition is injected directly into a diseased tissue tumor mass.
 39. The method of claim 35, wherein said composition is systemically administered.
 40. The method of claim 35, wherein a biological effect of said composition is at least 20% greater than that delivered in the absence of said composition.
 41. The method of claim 35, wherein said composition targets preferentially to a diseased tissue compared to a healthy tissue, thereby minimizing damage to said healthy tissue.
 42. A method for promoting an immune response in a subject, comprising administering to a subject the composition of claim 1, wherein said method comprises placement of said epitope on tumor cell or a cell in inflamed tissue of said subject. 